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AUTOIMMUNE DISEASE 

When the body goes awry 
Michael Craig Thigpen 
Tertnessee Scholars Senior Project 


i 
PREFACE 
I arrived at this topic for my Senior Project (boldfaced for emphasis) for my Tennessee Scholars 
Prgram in kind of a roundabout way. For about a year I spent my time working with Dr. Ranjan 
Ganguly in his molecular genetics laboratory dealing with Drosophila melanogasterfruit flies. I feel 
that my time there was rewarding, but not very productive. For the project I worked on, which I 
was going to use for my Senior Project, produced no real results. Whether this was due to my 
own character flaws (for I grew tired of counting flies) or truly due to problems within the 
experiment itself, I do not know. But I did know that if I was to turn something in I would need 
to find a new project to work on. 
I decided upon my present (and final topic) after I had taken a class in immunology in the fall 
of 1990 where we studied autoimmune diseases in the class for a week or so. The idea of the 
body's immune system attacking its own tissues intruigued me, so I decided to use this as pro­
ject. First, however, I had to sell my Tennessee Scholars' advisor, Dr. Bruce Wheeler, on the 
idea. This was actually no problem because he has always been very supportive of everything the 
Tennessee Scholars do. I wish to take this time to thank him for the years he spent with my class 
of Tennessee Scholars. He has been very patient with me and has been a very enjoyable person 
to work with. I wish him and his new Tennessee Scholars all the best. Now back to the paper. 
So with his blessing I began to research my topic. Now as I look back at the time I spent attempt­
ing to write this paper, I feel a great sense of accomplishment, but also a great deal of frustra­
tion. When I chose to do my Senior Project on this topic, I thought that I could write a fairly 
comprehensive study on the nature of certain autoimmune diseases. What I did not realize was 
that a comprehensive paper on this subject required a massive amount of research and writing. 
(I believe that I spent two weeks, almost day in and day out, simply typing this paper.) For the 
majority of the time I was working on this paper, I felt as though I were working on a book; it 
was just that tremendous. when I had started I believed that this would not be that demanding, 
for like most undergraduates who really do not get the opportunity to write such large papers 
the longest thing I had written was only about ten to fifteen pages long. This project has really 
opened my eyes to the effort it takes to get any piece of material published (even though I, by 
no means, attempted to get this project published), whether it is a popular novel or a scientific 
paper for a journal. For all the reasons above I wish to thank all my friends for helping me and 
being very patient with me while I struggled with this. I especially wish to thank my friend Wade 
Hunt for letting me use his computer and taking time out of his busy schedule to help me insert 
and position all the diagrams within this report. Without his help, I would not have finished this 
project and I am greatly indebted to him. 
In closing, I feel that I have produced a project very worthy of the Tennessee Scholars Program. 
In fact, I hope that this will aide the Program to recruit the best possible candidates in the 
future. 
Michael Craig Thigpen 
~~~~ 
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INTRODUCTION 
The body (human and otheIWise) is a remarkable piece of machinery. It is fairly self-sufficient, 
needing only a source of energy for nourishment. In addition, it is able to heal itself, to trans­
port itself, to think for itself, and countless other abilities which have only begun to be explored 
in depth. One of the most remarkable aspects of the body is the abllity to defend itself. The 
body will fight off any invaders which it may encounter and will remember these invaders in 
order to fight them offmore quickly the next time, if they reappear. So what happens when the 
body's defenses begin to malfunction. Most of the time this simply allows some type of bacteria 
or virus to cause infection. But what if this system is totally devastated one way or another. A 
classic example of this can be observed in those who have AIDS. In this case, the body no longer 
has any defenses against any type offoreign invasion; thus, the body is rapidly attacked and easi­
ly succumbs to the invaders. The mechanisms of autoimmune disease are almost exactly oppo­
site that which occurs in AIDS. In autoimmune disease it is not the failure of the immune 
system which causes problems for the body, but is the hyperactivity of certain immune responses 
which characterize this type of disorder. Autoimmune disease, specifically, is a disorder which 
occurs where the immune system malfunctions and begins to produce defenses against the 
body's own tissues. Common examples of these include lupus, juvenile diabetes, and rheuma­
toid arthritis. The problem facing most of those who have the disease and those attempting to 
treat them is that it is unknown what exactly causes autoimmune diseases. So unlike normal dis­
eases, there is not one factor which can be blamed. This makes trying to find a cure a much 
more difficult process. Many autoimmune diseases have been studied for over three hundred 
years and some even from the time of Christ. In comparison, the virus which causes AIDS, the 
human immunodeficiency virus, was isolated in only three years. So, needless to say, there is still 
a great deal of mystery surrounding these disorders. The purpose of thIS paper, therefore, is to 
attempt to dispel some of this mystery. 
There are basically two general groups of autoimmune diseases, those called organ-specific dis­
eases and those called collagen diseases (or better described as connective tissue diseases, for 
collagen is not the only type of connective tissue to be affected). Organ-specific diseases are 
those where the extent of the disease is generally confined to one organ. The autoimmune 
responses are also localized against protein compounds located on the diseased organ. On the 
other hand, connective tissue diseases are generally systemic diseases affecting many different 
organ systems at one time. The autoimmune response associated with these diseases are often 
directed against common components (i.e. RNA and DNA) which are seen in all of the diseased 
organs. 
In an attempt to give the reader a better understanding of the processes which occur in autoim­
mune diseases, an example of each type of disease (the two which probably have been studied 
the most) will be discussed within the text of this paper. But due to the complex nature of the 
connective tissue diseases, an example of an organ-specific disease. myasthenia gravis. will be 
addressed first. Then after this, systemic lupus erythematosus, an example of a collagen-vascu­
lar disease, will be discussed. 
1 
MYASTHENIA GRAVIS 
GENERAL INFORMATION AND HISTORY 
Imagine waking up in the morning after a very restful night of sleep and you begin your daily 
routine. But as the day continues you get weaker and weaker until you can't continue what you 
are doing. So you decide to take a rest. After an hour or so you feel much better, so you contin­
ue your previous activities. Once again you get weaker, but this time after just a little while. This 
scenario may sound like the person is simply out of shape when he or she actually may have 
myasthenia gravis, a debilitating autoimmune disease which affects the neuromuscular junction 
controlling many of the bodies' voluntary and involuntary muscles. This disease mimics the nor­
mal symptoms of being out of shape so closely that a person with myasthenia gravis who has not 
yet been diagnosed will often believe that this is the sole extent of the problems. In fact, this 
person will often begin a routine of daily weight training to become stronger when actually all 
he/she is doing is weakening him/herself. In order to prevent this from happening one must 
try to understand myasthenia gravis itself. 
The first mention of myasthenia gravis in scientific literature probably occurred when T. 
Willis described it in a report published in 1685, but there was still a great deal unknown about 
this disorder. Over the next two hundred years, there were only about seven cases ofmyasthenia 
gravis reported in the journals of period. Then in 1901 there was a breakthrough in the study of 
this disease. Two German scientists, L. Leopold and C. Weigert, discovered the importance of 
the thymus in myasthenia gravis as ascertained by the presence of a thymic tumor. This discov­
ery led to the use of thymectomy as a method of treatment. Then in 1961, the association of 
myasthenia gravis with a problem in the immune system was finally discovered by R. A. Good, et 
al. and byJ. F. A. P. Miller in separate reports published at the same time. Once these physicians 
made this observation there were many rapid advancements in the treatment and study of 
pathological mechanisms of this disease 
allowing much more effective care of 
aillicted patients. l 
Myasthenia gravis affects abou t four 
to six people out of every one hundred 
thousand (hardly a very common dis­
ease, but still one of the best under­
stood). It often affects women twice as 
many times as it does men. Women 
often become afflicted between the 
ages of twenty and thirty, whereas men 
become afflicted between the ages of 
forty and sixty. (This pattern of inci­
dence can be seen in many other 
autoimmune diseases including lupus 
which will be discussed later.) 2 
Specifically, myasthenia gravis (MG) 
is an autoimmune disease where an antibody response toward the acetylcholine receptor in the 
neuromuscular junction is produced. The term myasthenia gravis comes from Greek meaning 
"grave muscle weakness," which is actually what happens. Normally, a neurotransmitter (a spe­
cific chemical which plays a role in the transmission of an impulse from one nerve fiber to 
another) called acetylcholine (ACh) is released from the presynaptic terminal of the neuron 
and crosses the synapse. Once across, it attaches to a receptor specific for it (AChR, shown in 
Figure 1) on the muscle cell and causes the muscle to contract by producing a membrane depo-
Figure 1. Structure ojA ChRs in the postsynaptic membrane. Stud­
ies have Jound what subunits (shown in Greek letters)compose this 
rectptOT. The MIR is the main immunologic region where most 
antibodies bind. The other numbers show alternate antibody bind­
ing sites. 
- -
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larization. Next, a membrane-bound enzyme called cholinesterase degrades the ACh, so that 
the receptor can become free to accept another ACh signal. In myasthenic patients, however, 
these acetylcholine receptors are destroyed or interfered with so as to produce inadequate bind­
ing ofACh to produce depolarization of the muscle. Thus, this makes contraction of the muscle 
much more difficult, resulting in rapid muscle fatigue.2 A diagramatic summary of this process 
in shown in Figure 2. 
MG AS AN AUfOIMMUNE DISEASE 
Much of the research on the mechanisms of myasthenia gravis has been performed on rats 
which have been modified in a special way. These rats have been injected with acetylcholine 
receptors from other species in order to get an immune response which would also react to the 
rat's own AChRs. This cross-reactivity, which is due 
to the similarity between receptors from other NorlOal Myasthenia 
species, allows a condition to develop which is very 
"'etV91n1pUll~ N.rve Inpul ••
similar to that of human MG. This condition called cauau dI.c .... ~ Clue.$ oi JI:IIari. 
of AClt at O'ACtI lit
experimental autoimmune myasthenia gravis or myon.ural jYI'ICllon /\'11" ne., ,.1 juncticn 
EAMG was attempted in a variety of species, but the 
rat produced a syndrome which was most like that of T,8lI'51ll1t1." 
diffu'MS IcrQS.MG. The exact development of EAMG has been 
shown in Figure 3. The only difference between 
EAMG and MG in development is that patients with 
MG do not have any white blood cells which react to 
the antibody-receptor complex as in EAMG. All 
other characteristics are almost identical in both.3 AChi!; bl~ked 
frcll'llll$ rtcepfcr
I t has been found that there are three possible 	 "w Abs .~a1(]'1 
receptors 
ways that myasthenia gravis may affect acetylcholine ~~ ~ •• A~ •receptors. In each of these, the greater the effect is 
,en.•• /~k<¢V. 
on these receptors, the more severe the disease is. 
The first theory is the activation of complement (a 	 . .. .... .. 
. .... . - .... : : ; ...lytic substance in normal serum that combines with 
•.. - ........ 
antigen-antibody complex, producing lysis when the Musdtt i. MUICI4I15 nOl 
atil"ldl~ ..nd atirmlla_d;
antigen is an intact cell) on AChRs. It has been tontfACtlQn th.,..1& no 
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found by electron microscopy that in the membrane 
of the nerve postsynaptic terminal in myasthenic Figure 2. Comparison of narmal muscle function 
patients, there are fewer folds than those in normal and muscle junction in myasthenic patients. 
people. These fewer folds are in turn shallower and 
thus have a decreased area of contact with the presynaptic terminal as is shown in Figure 4.4 It is 
thought that this occurs possibly because complement along with immunoglobulins (a family of 
chemical compounds, abbreviated Ig, which include the antibodies), particularly IgG, act on 
AChRs to degrade and fragment this membrane. In support of this theory, scientists have found 
the C3 and C9 components of complement located within the neuromuscular junction. In addi­
tion they have found a general reduction in concentration of complement in the blood of myas­
thenic patients which occurs because at anyone time there is a limited amount of complement 
in the body. Thus, if there is an increase in complement activity (a process which includes the 
degradation of complement), then there must be lower levels elsewhere in the body until more 
complement is produced. Although complement is an important part of this mechanism, it is 
not involved in the next two theories myasthenia gravis affects acetlycholine receptors.5 
The second involves the blockage of the acetylcholine receptor by the antibodies produced 
against these receptors. Tests have shown that antibodies (also called autoantibodies in this 
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Figure J. Development ofEAMG. a)Normal neuromuscular junction with #1 showing the ACh in the 
presynaptic terminal represented by #2. The synapse and postsynaptic terminal are represented by #3 and 
#4, respectively. b)#l shows Ab binding to AChR. #2a and #2b show activation of complement. c)~ite 
blood cells attracted to the area by complement activity begin to attack the postsynaptic terminaL d) The post­
synaptic terminal #1 has fewer folds in it. The binding ofAb (#2) and activation of complement (#3) is 
an ongoing process further simplifying the membrane. #4 and #5 shllW further AChR degredation. 
NORMAL MG 
Afl£ASE 
5rT£ 
Figure 4. Comparison for normal and MG-associated junctions shllW increased simplification in the post­
synaptic membrane of the myasthenic neuromuscular junction. 
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case, "auto" meaning self) do bind to a portion of the receptor, but not the part that binds the 
ACh itself. It is thought that once the ACh binds to the receptor, it produces a special configu­
ration which allows the antibody to bind. Thus, there is no binding of Ab without ACh being 
present. This model, as is shown in figure 5, also explains how muscle strength decreases as 
physical activity increases due to the increased levels of ACh present.6 This possibility is very 
remote, though, because further tests in EAMG-amicted rats have shown that when comple­
ment is removed from the junction, antibodies bind to the receptor without negatively affecting 
the transmission. This leads most to believe that the antibody actually has little to do with the 
function of the ACh receptor.3 
The final mechanism by which acetylcholine receptors are thought to be affected is byaccel­
erated degradation of these receptors (figure 6a). This process has been studied the most of the 
three. It has been shown that accelerated degradation occurs because of cross-linking of the 
receptors by IgG antibodies. IgG is V-shaped, 
thus is able to bind and link two receptors 
together. This binding can lead to the forma­
tion of large clusters of receptors being 
formed with as many as sixty receptors in a 
single cluster (see figure 6b). This allows 
these receptors to be endocytosed as normal­
ly occurs, but at a much higher rate due to 
the greater concentration present in these 
areas (figure 6c). Once the AChRs have been 
endocytosed they are broken down by lysoso­
mal enzymes present within the cell (figure 
6d). Since these enzymes are present in con­
centrations independent of number of 
AChRs present within the cell, it is thought 
that the increased endocytosis is the rate-lim­
iting step of this process.5 
Myasthenia gravis was first thought to be 
an autoimmune disease for three main rea­
sons. The first involves the association of the 
thymus with this disease. Of those patients 
with myasthenia gravis, 75% have problems 
with their thymus, a gland which is involved 
with lymphocyte production and maturation. 
Specifically, 85% of the original 75% have 
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Figure 5. A possible theory on how Ab affects the acetyl­
choline receptor. 
hyperplasia (abnormal growth of normal cells) of germinal centers within the thymus. Within 
these germinal centers, formation and differentiation of lymphocytes occur; they also involve 
the parts required for Ab synthesis. In the other 15%, thymomas (tumor of the thymus) have 
been found.4 In either case, both can cause massive changes in the lymphocytes and antibodies 
being released. 
Most physicians also believe myasthenia gravis is associated with disorders in the thymus 
because there are certain muscle-like or "myoid" cells present normally in this gland. These 
myoid cells are very similar to normal muscle cells and even have AChRs. Therefore, many sci­
entists hypothesize that these cells provide the antigenic stimulus for an autoimmune response 
in myasthenic patients. In addition, the location of these cells in the body makes them very sus­
ceptible to immune attack. So it is generally believed that some slight change in these myoid 
cells or in the lymphocytes produced in this area may begin some type of autoimmune response 
5 
.... ." : . ~ ... 
t 
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Figure 6. Theory on how antibodies are able to cross link and destroy acetylchlmine receptors. 
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SYMPTOMS AND DIAGNOSIS 
For the most part, there is a pattern 
to the development of symptoms in 
myasthenic patients. Often the least 
severe conditions occur first, gradually 
becoming more debilitating as time 
goes on. Figure 7 shows the basic symp­
toms of myasthenia gravis. They often 
begin with the muscles which con trol 
the eye. Patients usually first by com­
plain that they have trouble moving 
their eyes and eyelids which can cause 
ptosis or drooping of eyelids and 
diplopia or double-vision. Next, the 
muscles which control facial expressions 
become affected. Instead of having nor­
mal expressions, often the person is 
only able to manage what is called a 
myasthenic snarl due to weak facial mus­
cles. 2 
The next muscles to be afflicted are Figure 7. Diagram which shows the primary areas MG can affect 
those used for speaking and chewing, and the basic symptoms which occur as a result. 
which are one and the same in humans. 
..,; .
.. .-.. . 
fac., eyes, lips, 
longu., and throat 
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involving antibodies which also react with normal AChRs in the rest of the body leading to a 
full-blown case ofMG. 5 
The second reason that myasthenia gravis was suspected to be an autoimmune disease was 
that it often co-exists with other autoimmune diseases, such as rheumatoid arthritis and systemic 
lupus erythematosus. 5 The final reason involved, the reduced complement levels in an afflicted 
person's blood, was described earlier. Reduced complement levels are also found in many other 
autoimmune diseases. 
This causes a myasthenic patient to sound drunk and also to have problems chewing solid 
foods. But even if a person is able to chew food well enough to shallow, he/she may not be able 
to because ofweakness of the muscles in the neck which are needed for swallowing. These mus­
cles are often next to become diseased. Due to problems with swallowing, more severe cases of 
myasthenia may require intravenous solutions to be used.2 
Myastenia gravis often attacks the muscles located in the neck (needed for holding the head 
up), the arms, and the legs next and later on, the respiratory muscles, the last group of muscles 
to be affected. Problems with these muscles cause many great difficulties for the myasthenic 
patient, especially with breathing. For this reason, once patients reach this level of severity, med­
ical care is needed almost immediately. Often patients require a mechanical respirator to help 
them breathe.2 • 
There are three methods for the diagnosis of myasthenia gravis, but usually all three are per­
formed so that there can be no question about what disorder the patient has. The first one per­
formed is usually the electromyogram where a muscle is repeatedly stimulated to get an action 
potential (the electrical activity developed in a muscle, nerve or the central nervous system dur­
ing activity). A rapid decline in action potential is a sign of myasthenia gravis. The next method 
to test for MG is the Tensilon test. Tensilon (edrophonium chloride) is a very short-acting anti­
cholinesterase drug which destroys the cholinesterase which in turn destroys ACh. Thus, there 
7 
is more ACh present to enhance contraction. Thirty to sixty seconds after Tensilon is given, 
muscle strength dramatically increases. This improvement usually lasts for about four or five 
minutes. Such a result is a positive test for MG. The final test for myasthenia gravis is a blood 
test which simply tests for the presence of antibodies made against the acetylcholine receptors. 
Ifall three of these tests are positive, then it is safe to say that the person has this disease.2 
TREATMENT 
Although there is no cure for myasthenia gravis (in humans at least), there are several ways 
to treat it. The first is the use of the anticholinesterase drugs which are given to help improve 
the effects of acetylcholine on muscle, as was described earlier. These drugs often include pyri­
dostigmine bromide (commonly called Mestinon), neostigmine bromide (Prostigmin), and 
ambenonium chloride (Mytelase). Table 1 shows the many side effects of these drugs. The next 
method of treatment also involves the use of drugs, but these drugs suppress the immune 
response involved with myasthenia gravis. Steroids such as prednisone are often the drugs given 
as immunosuppressants. They work by inhibiting the release of Ab and by slowing the other 
immune responses associated with MG.' These drugs must be administered in a closely regulat­
ed environment due to their effect on the entire immune system. The side effects of steroids as 
immunosuppressants are also displayed in Table 1.2 Other immunosuppressants could also be 
administered instead of steroids, but these are often given only as a last resort because of the 
harsh side effects (as shown in Table 1) they have and the devastating effect they have on the 
immune system. These immunosuppressants often include drugs such as azathioprine and 
cyclophosphamide.2 (These drugs will be discussed at length in the lupus portion of this 
report.) 
The next two methods of treatment are more physical than the chemical nature of the last 
two. The first is the surgical removal of the thymus gland, which lays on either side of the tra­
chea. This procedure was first performed only on patients with thymomas until physicians real­
ized the benefits that this procedure provides to other myasthenic patients (as was realized from 
Leopold's and Weigert's report). There are two different ways that the thymus may be removed. 
The transsternal approach involves the splitting of the sternum in order to gain total access to 
the thymus. Because this procedure has a little more involved with it than the next, there are 
many problems associated with this method. These complications include a slightly longer rate 
of recovery and a somewhat higher death rate associated with this approach because the ster­
num is totally split. The other method of thymectomy is the suprasternal approach where only 
a small incision above the sternum is made in order to reach the thymus. The thymus then is 
surgically removed. The main problem associated with this method is that the entire thymus 
may not be removed. Either approach is readily acceptable, though.2 
The final method of treatment is by plasmapheresis a procedure that simply lowers the 
amount of autoantibodies to the AChRs in the patient's blood. In this procedure, blood from a 
myasthenic patient is removed and centrifuged to separate the cells (red blood cells, white 
blood cells, others) from the plasma which contains the antibodies. The cells are then returned 
along with fresh plasma to the patient's bloodstream.2 This procedure, not totally accepted in 
medicine, is used only as a temporary measure to help. 
One of the major problems with treatment with drugs is the possibility of either a myasthenic 
or a cholinergic crisis occurring. A myasthenic crisis occurs when there is a removal from or a 
change of medication. This crisis can last up to a few months. During this time a patient may 
require a ventilator and/or an intravenous line to gain needed fluids. This condition is often 
treated by increasing doses of medication or returning to the medication formerly given. A 
cholinergic crisis may result from an overdose ofanticholinesterase drugs. A cholinergic crisis is 
treated often by an antidote called atropine sulfate, a cholinergic drug which blocks ACh activi­
8 
ty. Diagnosing the proper crisis is often very difficult, though, because they both have very simi­
lar symptoms as is shown in Table 2. The main way to distinguish between the two is to perform 
a Tensilon test. If a person is having a myasthenic crisis, then after the Tensilon is added the 
patient gets dramatically better until the drug wears off. Whereas if a cholinergic crisis is occur­
ring, then patient will not respond to the addition of the Tensilon.2 
While there is no absolute cure for MG, one may be on the horizon. Some experiments have 
successfully been performed where EAMG rats have been cured of this disorder. One method 
involves the growth of cultures containing certain lymphocytes (a type which suppresses 
immune responses in normal individuals) specific for AChRs and the receptors themselves, in 
the presence of immunosuppressants. Mter these lymphocytes are combined with lymphocytes 
from an afflicted individual, the mixture is reinjected into the diseased rat. Results have shown 
that the autoantibody response is inhibited without affecting normal immune response.8 
Another method which has been used involves monoclonal antibodies (MAb) directed 
against the lymphocytes which encourage such an autoimmune response. Monoclonal antibod­
ies are antibodies which are produced by a clone of antibody-forming cells and, therefore, are 
identical. In this approach, researchers tagged these antibodies with a chemical which is toxic 
to the lymphocytes. Since the MAb are specific for only the proper lymphocytes, only those 
secreting autoantibodies were killed. Hopefully, tests of both procedures in humans will be as 
promising.8 
Still there are many problems involving myasthenia gravis encompassing every area dis­
cussed above. The greatest problem though is understanding the disease itself. As with other 
autoimmune diseases, very little is known about how the disease starts. Until this is discovered 
very little can be done to find a cure. And without a true cure, thousands of people will have to 
continue to suffer with only hope keeping them going. The future for those with lupus is even 
more dismal. Because of its systemic nature and potential fatality, this is even more true for 
those afflicted with systemic lupus erythematosus or simply lupus. This disorder will be dis­
cussed in the next section. 
9 
SYSTEMIC LUPUS ERnHEMATOSUS 
GENERAL INFORMATON AND HISTORY 
"The Great Imitator," that is how lupus has been described in modern-day medicine. "The 
Great Imitator" was a title which physicians reserved for syphilis or cancer in the past because of 
the way they would mimic other diseases while becoming insidiously more destructive in the 
meantime. But with the advancements of science and medicine in the twentieth-century, these 
diseases have become much easier to diagnose. Only lupus remains a mystery.7 "The Great Imi­
tator," how else would you refer to a disease in which no infectious agent has ever been isolated 
and the symptoms most often seen at the onset are fever, general malaise, and occasionally a 
rash, yet the disease only ten to twenty years ago was almost always fatal within five years. While · 
life-expectancy has increased dramatically in recent times, due in large part to more liberal use 
of drugs to curb the autoimmune reactions, much is still unknown about lupus, reflected by the 
amazing number of incorrect diagnoses of lupus. Table 3 shows a list of a number of diseases 
which have been incorrectly interpreted in patients later found to have lupus. So how can lupus 
be treated when it is difficult to diagnose. This section will discuss this, along with the symp­
toms, known physiological information, and the meth­
ods of treatment presently used (along with the side 
effects which arise due to these treatments). 
Systemic lupus erythematosus (SLE) was probably 
first described two thousand years ago by Hippocrates 
when he wrote of a disease which eroded away the skin 
and flesh of the face. He spoke of this affiction as some­
thing which all people including physicians feared. It 
was not until the 19th century when the name lupus was 
given to the disfiguring condition characterizing this dis­
ease. Lupus, meaning wolf in Latin, was named so 
because many thought the disorder looked as if it had 
been caused by the bite of a wolf.7 In a paper written by 
Pierre Cazenave in 1852, he was the first to name this 
disease, lupus erythemateux or lupus with redness.9 It Figure8. Clossic example ofan IE cell. 
was not until 1872 that SLE was first thought to be a sys­
temic disease by Moritz K. Kaposi (as in Kaposi's sarcoma, seen most often in AIDS patients), an 
idea which was later proved in 1895 by William Osler. 1 
One of the major events in the history of lupus was the discovery of the LE cell, which later 
became the first diagnostic test for SLE. The LE cell, discovered by Malcolm M. Hargreaves, was 
later found to occur in as many as 80% of those with lupus compared to only about 4% of those 
with rheumatoid arthritis (although some studies show this to be as high as 27%)10 and less 
than 1 % of patients with other autoimmune diseases, according to figures published by the 
American Rheumatism Association, the governing body which oversees the treatment of many 
autoimmune disorders including SLE.7 One of the most important aspects of this discovery, 
however, was the association of the LE cell with antinuclear antibodies (ANA), antibodies which 
are directed against the nucleus and nuclear material of a cell. What Hargreaves described was 
the attack of one white blood cell called a polymorphonuclear leukocyte (PMN) on another of 
its own kind. Apparently in this process, the healthy PMN enters the cytoplasm of the altered 
PMN possessing the ANA and phagocytoses (engulfs) the other's nucleus, resulting in what is 
called a LE cell (Fig. 8). The cytoplasm, however, is not bothered by the invading phagocyte, 
only the nucleus. The engulfed nucleus most often will assume the shape of a round purplish 
(due to the stain used in the test) sphere of uniform nature, resulting from the ANA attached 
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on the outer surface.9 This discovery led to many others, which will be discussed later, involving 
the role ofANA in lupus. 
INCIDENCE 
Systemic lupus erythematosus can occur in men and women alike, of all ages, but a large pro­
portion of those affected are women of childbearing age. About 89% of the cases of SLE are in 
women with an average age of onset being around 29 or 30 years old. This is opposed to the 
average age of onset in men which is around 51 years old. During the childbearing years, the 
ratio of women to men with SLE is around ten to one, if not fifteen to one. Mter menopausal 
age (around fifty-five), the ratio drops to only about two to one as shown in Figure 9. This 
imbalance, thought to be caused somehow by the sex hormones, will be discussed in length at a 
later time.7 
In the general population, lupus is thought to affect around one in every eight thousand.10 
Yet it affects about one in every seven hundred white women between the ages of 20 and 64 and 
one in every two hundred and forty­
,five black women within the same age . 
range.1 1 Although there are no con­
crete theories on the reasons for this 
higher incidence of SLE in non-white 
ethnic groups, there have been some 
statistical studies of the various autoim­
mune diseases, revealing an increased 
prevalence of some diseases in certain 
latitudinal regions. For example, stud- ' 'J 
ies have shown that multiple sclerosis is 
most prevalent between the latitudes of 
40° north to 60° north and 40° south 
to 60° south. It is about forty times o 
more common in Minnesota than . '0 
Mexico City.7 In addition, one study by 
Marian Ropes showed a higher per­ Figure 9. Ratios ofwomen to men with SIE ofdifferent age ranges. 
centage of those with SLE in the study 
from the latitudes of the Mediterranian countries. Of the 134 patients in the study, 60 (46%) 
were from Mediterranian countries, another was from the West Indies (which has the same 
range of latitudes as those countries along the Mediterranian), two more were Afro-Americans, 
and one final patient was Asian-American. Even including the fmal three patients in the previ­
ous listing as non-Mediterranian natives, the incidence of patients from all areas other than 
those of the Mediterranian was only 54%.10 Whether this correlation simply reflects local envi­
ronmental factors (or prevalence of viral influences) in these areas which activates autoimmune 
disease at a higher rate or whether this, in fact, reflects a basic genetic difference which evolved 
over time in different ethnic groups of various regions is unknown. But this no doubt could 
explain why SLE is more evident in non-white groups, especially those ofAfro-American and, to 
a lesser degree, Asian-American heritage. 
SYMPTOMS 
The symptoms of systemic lupus erythematosus are wide-ranging and dependent on the 
patient, for any patient can develop only one or all of the symptoms. In addition, unlike in myas­
thenia gravis, the symptoms of SLE do not follow any type of sequence. Symptoms which are 
more severe in nature can develop at the onset of the disease almost as frequently as those which 
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are less severe. The most common of the symptoms are general malaise, weight loss, fever, and 
generalized weakness. Those diagnosed with SLE experience fever at the onset about 25% of the 
time,9,lO a persistent fever later after diagnosis about 80% of the time, and fever at one time dur­
ing the course of the disease at least 90% of the time.7 This fever generally remains around 100°F 
during the course of the disease, although a majority of patients have a fever of over 103°F at any 
one time. Fevers as high as 106° and 107° have also been reported.1 0 Malaise is seen in about 
18% of cases at the onset and in almost 100% of cases at anyone time.9 In addition, those with 
SLE have weight loss and fatigue in about 65% and 75% of patients, respectively.7 
One of the major areas affected by SLE is that of the skin. The manifestation which is most 
commonly associated with lupus is the classic "butterfly" rash. The rash, one of the frrst symp­
toms described as being due to lupus, was first named this by Ferdinand von Hebra in the 1840s 
when he wrote of it as being "not dissimilar to a butterfly."7 The rash itself, often found in 50% 
of SLE patients,12 consists of a general redness of the skin 
(due to congestion of localized capillaries) mostly located on 
the cheek bones and meeting across the bridge of the nose 
(figure 10).9 
Many other lesions are sometimes associated with SLE. 
The most common, called discoid or disk-like skin lesions, 
are found in about 20% of patients. In general, discoid 
lesions are elevated, reddish patches of rough and scaly skin 
located on the face mostly and at other times on the ear 
lobes, the back of the neck, the chest, the shoulders, the 
back, the arms, the hands, the fingertips, and the feet. Doc­
tors also often see in around 40% of patients a sensitivity to 
the sun which makes the rash break out worse.9 Discoid 
lesions can also occur as two subtypes which differ somewhat 
from other disoid rashes, vasculitic and another subtype 
described as lupus profundus. Vasculitic lesions are mainly 
tender to the touch, hardened somewhat, and are mostly 
located on the forearm, fingertips, or soles of the feet, and 
also on occasion found around the ankles where they often Figure 10. Classic example of butterfly 

become ulcerated, later infected, and generally have difficul- rash as seen by a slight redness of ar­

ty in healing. The lesions associated with lupus profundus are lain areas. 

generally deep cutaneous nodules appearing as hardened 

lumps which can be either tender or nontender. These lesions are not as common as the vas­

culitic type.l 2 Several examples of discoid lesions are shown in figures 11, 12, and 13. 

Other skin lesions can include the maculopapular lesions which are characterized by the 
presence of small elevated bumps, often discolored compared to the rest of the body's pigmen­
tation. (figure 14) Ulcerated lesions of the mucous membranes in nasal and oral regions can 
also be observed in as many as 40% of those with SLE. These lesions are often painless at first, 
becoming tender and much deeper as the disease progresses(figure 15).12 Loss of hair due to 
the affliction of the scalp with various types of lesions, as shown in figure 16, is also observed. 
This occurs in anywhere from 25% to 50% of patients depending on the study.7,12 
The joints and muscles of the patient are usually the next areas of affiiction commonly 
observed. The joints are affected in about 90% of patients at anyone time.7 The joints most 
often troubled are those of the hands, knees, and wrists; less common are the joints of the 
ankles, the elbows, and the shoulders (occasionally also the spine and the hips are affected)9. It 
is also fairly common (found in about half of patients) for severe morning stiffness to occur.12 
The occurrance ofjoint pain can also be coupled with swelling, occasionally causing a diagnosis 
12 
Figure 11. Rough seal" Fill"" 12. Cutaneous lesions in 22-year-old 
lesions characteristic of a dis­ woman. 
coidrwh. 
Figun 13. Discoid lesions appearing as a seal, rash. 
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Figure 14. Maculopapular rash on the elbow of a 22-year-old Figure 15. Rash on the bottom of the tongue of 
male. a 22-year-old white male. 
Figure 16. Loss of hair due to infection of the scalp caused 
by SLE. 
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of either rheumatoid arthritis (RA) or rheumatic fever to be reached. One study found the 
changes caused by SLE to be identical to those caused by RA in about 25% of the patients they 
studied. Figure 17 shows an example of arthritis known to be caused by SLE, yet appears to be 
very characteristic ofRA.9 Comparison of SLE and RA in regard to differential diagnosis will be 
discussed at a later time. About one-fourth of the patients known to have SLE complain about 
myalgia or muscle aches.7 Occa­
sionally in more severe cases, the 
muscles of the hands become weak 
and atrophied, in addition to the 
normal aches seen. This condi­
tion, however, is not very com­
mon.9 
SLE also often affects the circu­
latory system including the heart. 
In SLE, all three layers of the heart 
- the pericardium, the myocardi­
um, and the endocardium - can 
become affiicted; about one-half of 
patien ts have some type of heart 
involvement.9 Inflammation of the 
pericardium, the membrane which 
surrounds the heart, is diagnosed 
most often, with an occurrance of 
about 25%. The infection of the 
myocardium, the actual heart mus­
cle, is observed less often in diag­
nosis (less than 10% occurrance, 
according to one study) 10, but 
upon autopsy can be seen in about 
42% of cases) 2 Endocarditis, infec­
tion and inflammation of the inter­
nal lining of the heart, is also not 
observed very often in diagnosis, 
but is present in as many as 50% of 
patients upon autopsy)3 Most of 
the pathological nature of endo­
carditis and pericarditis involves 
the formation of fibrinous tissue 
over that of the normal tissue. In 
pericarditis, fibrin (an insoluble 
protein which is responsible for 
the essen tial portion of a blood 
clot) attaches itself to the pericardial membrane, causing the membrane to become very rough. 
This new texture of the pericardium often causes a type of murmur (a gentle blowing sound 
heard during heartbeats upon direct examination of the chest) due to the increased friction 
between the membranes. This murmur is often followed by entry of fluid into the pericardial 
sac)4 In one study this pericardial murmur, or rub as it is also called, was found in about 30% of 
the patients tested, along with a presence ofpericardiaI fluids in 17%)0 
The endocardium is also affected by the growth of fibrin on its tissue. The fibrin associated 
Figure 17. Generalized swelling and decalcification of the bones of the 
hands as seen in the same man four years later. These conditions are 
almost identical to those seen in RA. 
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with endocarditis forms vegetations mostly upon the valves of the heart which have become 
ulcerated by the disease. According to one report, these ulcerated lesions are found in approxi­
mately 23% of patients with SLE, compared to that of only 3% occurring within the normal 
population. The same study showed that the vegetations are found in about 7% of those with 
SLE, compared with 0% prevalence in the control group. However, there was a much higher 
incidence (16%) of these vegetations occurring in SLE patients who had antibodies against 
compounds called phospholipids, which are located in the heart as well as much of the rest of 
the body, than those who did not have these antibodies (1 %). Therefore, most believe that the 
presence of these antibodies are responsible somewhat for the formation of these fibrinous 
growths.l3 Endocardial murmurs, found at about the same rate of incidence as the pericardial 
murmurs, are also associated with these growths on the endocardial tissue.l 0 
Myocarditis, on the other hand, does not usually involve fibrin growing on the outside of tis­
sue, but instead fibrous tissue often develops between the layers of heart tissue. Symptoms 
which are in this type of infection 
are as follows: dyspnea (difficult or 
labored breathing), orthopnea 
(inability to breathe except in an 
upright position), enlargement of 
the heart, and occasionally heart fail­
ure. Despite the severity of myocar­
dial involvemen t, there is usually 
little reason to worry, for the possi­
bility of this happening at all, much 
less to this degree, is very remote.9 
The lungs become affected in 
SLE at about the same frequency as 
the heart and the circulatory system. 
At the time of diagnosis, inflamma­
tion of the pleura (see the glossary), 
usually accompanied with accumula­
tion of fluids, is present in approxi­
mately 11 % of patien ts. About 45 % 	 Figure 18. X-ray slwwing large amounts of pericardial and pleural 
fluids, along with inflammation ofthe pleura.
of SLE patients experience pleuritis 
at one time or another during the course of the disease. Figure 18 shows inflammation of the 
pleura along with pericarditis, as was described earlier. One main disorders which can accompa­
ny pleuritis is acute lupus pneumonitis (inflammation of the lung without gross toxemia) usual­
ly seen with vast hemoptysis (bloody sputum), cough, chest pain, dyspnea, and bleeding within 
the lung.l 2 
The kidney is perhaps the most involved organ in SLE; renal dysfunction is seen in at least 
half of patients at some time during their affliction. The most common way to test for deteriora­
tion of the kidney is by urinalysis, which detects the presence of protein and cellular compo­
nents in the urine. Although an abnormal urinalysis indicates kidney disease to some degree, a 
normal one may not be a sign of normal renal function. Tissue samples from the kidneys of 
some patients can show severe damage, yet the person may not have any of the signs of renal 
dysfunction.I 2 Even if urinalysis may not always be proof positive of disease, it still is a good test 
to discover the beginning stages of SLE, for the presence of protein and blood components in 
urine may actually occur before the formation of skin lesions. Later as the disease progresses, 
amounts of leukocytes (type of white blood cells), erythrocytes (red blood cells), and protein 
are excreted in the urine along with casts of transparent cellular material and fine 
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granules(examples of the casts are shown in figure 19). A severely affected kidney later will 
show casts of red cells, white cells, and course granules. Other symptoms of renal dysfunction 
are anasarca (generalized swelling throughout the entire body), hypoalbuminemia (abnormally 
low albumin content in the blood), and only a small change in blood pressure. SLE-associated 
kidney disease is not the only affliction possessing these symptoms, however. Other types of 
nephrosis also possess a majority of these symptoms; the one distinguishing factor between the 
two is the fact that patients with non-SLE 
kidney disease often have elevated levels of 
cholesterol in their blood, a factor which 
does not occur in SLE.9 
Other less commonly affected organs 
include, according to frequency (depending 
on the study), the central nervous system 
(eNS), the lymph nodes, the gastrointesti­
nal tract, the eyes, the liver, the pancreas, Figure 19. 
and the spleen.9,12 One of the main symp­
toms used for diagnosis of SLE is the presence of certain mental disorders which can include 
convulsions, involuntary jerky movements, drooping of eyelids, double-vision, psychosis, 
meningism (a hysterical simulation of meningitis), aphasia (defect of the power of speech, writ­
ing, or signs, or of comprehending spoken or written language), and paralysis. Other condi­
tions such as irritability, restlessness, disorientation, confusion, and even coma* can be seen in 
SLE patients. Unfortunately, many of these afflictions can also occur in a variety of other mental 
disorders such multiple sclerosis, epilepsy, and mental instability. In fact, one study showed that 
a patient had received psychiatric care for seventeen years before a diagnosis of SLE was finally 
ascertained.9 
The prevalence of these disorders also make it difficult to reach the correct diagnosis. Those 
with SLE have some type of mental syndrome affecting the eNS (which includes the brain and 
spinal cord) at least 37% of the time and at the most around 75% of the time, depending on 
the study. Interestingly enough, the peripheral nerves (which include all the nerves outside the 
eNS) are rarely affected, usually only in 10% of cases at the most. This may be due to a high 
incidence ofwhite blood cells, specifically lymphocytes and PMN leukocytes, and protein in the 
fluid which surrounds the central nervous system. The formation of lesions within the vascular 
system of the brain may be a direct result of this. These lesions are thought to be responsible for 
many of these conditions, primarily the convulsions. They are not commonly found in those 
with peripheral nerve involvement, however. Involvement of peripheral nerves can be observed 
by an increased activity of reflex actions and spasms, inflammation of the nerves, and the loss of 
certain senses.9 
During the course of SLE affliction of the lymph nodes may occur, occasionally leading to 
the diagnosis of lymphoma or mononucleosis,12 Enlargement of the lymph nodes, sometimes to 
the extent actually observed in lymphoma, assists the doctor in making an incorrect diagnosis. 
Those which are most often afflicted are, in order of frequency, the axillary lymph nodes (locat­
ed under the arms), the cervical lymph nodes (located in the neck), and the lymph nodes of 
the abdomen and chest. These conditions occur more often in children than in adults and 
more often in blacks than in other groups.9 Overall, approximately half of those with lupus will 
* There have been many reports of patients which show no other manifestations of SLE, except for the fact that they 
remain in a catatonic state for months at a time. These patients seem to be somewhat conscious of their situation as can 
be seen in their eyes. But for the most part, they have no other acknowledgement of the world around them. Move­
ments (except for the eyes) can be non-existent for the entire duration of this episode. Catatonic states such as this 
begin without warning and can disappear just as quickly, leaving the patient generally able to perform tasks as usual. 
The cause of these episodes is unknown.15 
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experience lymph node involvement.12 
About 40% of people with SLE have some gastrointestinal tract problems. Common symp­
toms, which can range from almost non-existant to extreme severity (usually requiring surgery), 
include nausea; vomiting, often including blood; loss of appetite; abdominal pain and cramps; 
and diarrhea, which can also include blood. Occasionally, a patient will also have inflammation 
of the colon and ileum (both part of the intestinal tract), difficulty swallowing, and a burning 
feeling within the abdomen. Many of these symptoms result from complications involving the 
circulatory vessels within the gastrointestinal wall. Inflammation of arteries and formation of 
ulcers on the bowel wall are common examples of these complications. However, some symp­
toms may be the result of problems in the liver, pancreas, spleen, and lymph nodes.9 
Although damage to the eye is uncommon in 
SLE, some studies have shown that the eyes can 
be affected in as many as thirty percent of cases 
(one study even reported an incidence of over 
fifty percent). SLE usually causes hemorrhaging, 
inflammation of the optic disk, and general 
accumulation of fluids with the eye. Retinal atro­
phy, which also occurs on occasion, often results 
in the formation of fibrin patches replacing 
these areas (figure 20). Less commonly observed 
symptoms include a hardening of the eye (often 
with an excess of blood in the eye) and inflam­
mation of membranes and tissue immediately 
surrounding the blood vessels in this area.9 
The pancreas, liver, and spleen are the last 
organs to be discussed. Enlargement of the liver 
(hepatomegaly), along with increased levels of 
liver enzymes, occurs in about 30% of SLE Figure 20. Retinal exam shows many white patches 
which are fibrin growths replacing areas ofretinal dete­
patients. This percentage is even higher in those noration. 
who take large amounts of nonsteroidal anti-
inflammatory drugs (NSAIDs) which include aspirin and ibuprofen.12 Occasionally a condition 
called "lupoid hepatitis" characterized by the presence ofLE cells, large amounts of antinuclear 
an tibodies, and active liver disease occurs. Laboratory tests (excluding tissue sampling) rarely 
show liver disease in those SLE patients with this affiiction, however; thus, the probability of 
recovery from this syndrome is very low.9 
Infection of the pancreas (very rare)lO and the spleen (around 20% of cases) 12 also occur 
occasionally, often due to other conditions. Inflammation of the pancreas usually is present in 
those who previously had disease of the pancreatic arteries. Symptoms attributed to enlarge­
ment of the spleen (splenomegaly) and other malfunctions commonly begin after or actually 
are the result of hepatomegaly. Furthermore, disease of both the liver and the spleen may, in 
return, be associated with the affliction of the abdominal lymph nodes.9 
DIAGNOSIS 
As has been referred to many times previously, diagnosis of SLE is a very difficult process fac­
ing the physician. Years ago, it was solely at the physician'S discretion as whether to diagnose the 
disease that a certain patient had, in fact, as systemic lupus erythematosus. This decision usually 
correlated with the physician's experience, although not totally. An inexperienced physician 
could miss the correct diagnosis for many years, as could an experienced physician when pre­
sented with a set of symptoms, which he/she had not come across before as signifying SLE. 
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Then in 1971, the American Rheumatism Association (ARA) published a list of criteria to aid in 
the diagnosis of SLE. The list, shown in its entirety in table 4, was compiled by sUIVeying large 
numbers of physicians in both the United States and Canada as to which symptoms most com­
monly occurred in cases of SLE. The ARA then judged these symptoms on how specific they 
were for SLE and only SLE. Out of nearly sixty items, fourteen of them made the list; of these 
fourteen, the occurrence of four at one time or another would positively prove the presence of 
lupus. Although this list greatly helped physicians, others criticized it for having some symptoms 
which were not considered specific 
enough and excluding others which , 
were well-known to be indicative of 
SLE. In order to remedy some of the 
disagreement over the list, the ARA 
revised its list in 1982, cutting the num­
ber of criteria to eleven (as with the 
previous list, the occurrence of four of 
these still proved the diagnosis of SLE) 
while modifying those which 
remained.7 Table 5 shows this list in its 
entirety. 
There are a couple major differ­
ences between the two lists. Raynaud's 
phenomenon (Figure 21) and alopecia 
which are very general symptoms found 
in a wide range of other disorders were 
not included in the revised list. But per­
haps the greatest change between the 
lists is the introduction of tests for 
antinuclear antibodies. When the ARA 
produced the first list of criteria, there 
was not enough information on the sig­
nificance ofANAs. It turns out, howev­
er, that ANAs are very specific for SLE. 
Around 90% of SLE patients have high 
levels of ANAs, compared to less than 
5% of other patients.12 (Some people 
within the normal population also have 
these antibodies, along with some other 
types of autoantibodies, but in extreme­
ly small proportions; Table 6 shows a 
list of autoantibodies found within the 
normal populations of certain 
species.) 17 Those with rheumatoid 
arthritis also have these antibodies 
about 67% of the time, but generally in 
lower levels. (Some "drug-induced" lupus patients also show some types of ANAs, but not all.) 7 
The presence of these antibodies allow SLE to be tested for much more easily. There are many 
types of antinuclear antibodies as shown in table 7. These antibodies are for specific antigens 
and, therefore, require more specialized tests In order to discover exact levels of these. Usually, a 
general ANA test is first performed to discover the presence of ANAs and then other tests are 
Figure 21. An example of the two phases seen in Raynaud's pM­
nom eno n. The photo at the top shows the first phase, that of 
increased paleness in certain fingers. This phase ends as blood 
begins to circulate in these areas. This leads to the next phase which 
is slwum in the photo at the bottom. 
19 
done to find the specificity of the antibodies. Figure 22 shows the technique behind the ANA 
test. The test begins by adding serum from a patient, possibly possessing antinuclear antibodies, 
to a container layered with antigens, known to bind the antibodies which are being tested for. If 
the proper antibodies are present, then they will bind to the antigen substrate. Whereas if the 
antibodies which are present are not specifically produced against these antigens (e.g. antibodies 
which are not ANAs), then there is no binding. After the mixture is washed to remove the 
unbound antibodies, a fluorescently marked antibody reagent, which binds to the antibody-anti­
gen complex, is added to allow the detection of these antibodies visually. Thus, a sample will fluo­
resce if ANAs are present and will not, they are not present.12 A sample, positive for ANA, is 
shown in Figure 23. 
One of the problems with SLE, 
however, is that antibodies against a 
wide range of other tissues are pro­
duced (as shown in Table 8) and not 
just antibodies to nuclear material. 
These antibodies cause a wide range 
of other important conditions (all of 
those mentioned below are on the 
ARA list of criteria) which can be 
detected by other laboratory tests.* 
One of these conditions is acu te 
oWrp' ~"'.(A\t 
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hemolytic anemia found to occur in 
less than five percent of SLE patients 
as a result of an tibodies produ ced 
against the red blood cells (erythro­
cytes). Other problems such as high 
bilirubin content in the blood, an Figure 22. Principle ofANA Test 
abnormal increase in the number of 
young red blood cells, and enlargement of the spleen often accompany this condition. Corticos­
teroids have been found to suppress this activity, but not without certain side effects as will be 
discussed later. Occasionally, a doctor recommends a splenectomy for the patient to alleviate 
some of the symptoms, even though this procedure has not been proven to help cure the ane­
mia.9 In addition, splenectomy does make the SLE patient more susceptible to certain infec­
tions, especially pneumonia, however.7 
Laboratory tests also occasionally show leukopenia (reduction in the number of leukocytes in 
the blood) in some SLE patients; studies show that 71-81 % of SLE experience this on one occasion 
during the course of the disease. The reduction of leukocytes, a type of white blood cell, is also a 
result of autoantibodies directed against these cells. Specifically, leukopenia occurs when the cell 
count goes below 5,000 per cubic millimeter;9 one study even reported finding a patient with a 
leukocyte count as low as 450 per cubic millimeter.10 Normal values range from 4,500 to 11,000 
leukocytes per cubic millimeter. 18 Another autoantibody mediated condition, a general reduction 
in platelets (thrombocytopenia), is encountered in about 50% of patients with SLE. Some hemor­
rhaging of capillaries may accompany this condition, which is defined as occurring when there are 
less than 100,000 platelets per cubic millimeter.9 (Normal values range from 150,000 to 400,000 
platelets per cubic millimeter) 18. Some studies have reported counts as low as 7,000.10 
One of the more unusual lab findings associated with SLE is that of the chronic false-positive 
* These conditions could have been possibly described in the section on symptoms, but the author thought the direct 
correlation between these and autoantibody activity neccessitated their discussion in this section. 
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test for syphilis which occurs in approximately 10-20% of patients, who have no other signs of 
syphilis. This false-positive test usually remains positive over long periods of time (ARA guide­
lines for diagnosis of SLE require the patient to be false-positive for at least six months before 
the test can be indicative of SLE). While the exact cause is unknown, there has been some evi­
dence linking autoantibodies to this phenomenon.9 To prove a positive result is actually a false­
positive, one of two more specific tests can be performed. One is the Treponema pallidum (the 
organism which causes syphilis) immobilization test which is slowly being replaced by another 
more sensitive test, the fluorescent treponemal antibody absorption test.II 
Diagnosis -Relation to other Diseases 
Even with all the lists and cri­
teria to help with the diagnosis 
of SLE, there are still many prob­
lems associated with distinguish­
ing SLE from other diseases. The 
greatest problems are with distin­
guishing rheumatoid arthritis, 
discoid lupus, and "drug­
induced" lupus from SLE. 
Rheumatoid arthritis has many 
of the same general symptoms as 
SLE does; symptoms like fever, 
malaise, loss of weight, and 
inflammation of muscles and 
joints are very common in both. 
But since rheumatoid arthritis 
occurs at a higher rate, many Figure 21. An example ofa positive ANA Usl. This pattern off1:uurescence 
cases of SLE have been diag- indicates tIu pmmct ofanti-DNA antibodies. 
nosed as RA. In some patients 
there is very little evidence to contradict this diagnosis. X-rays can show very little difference 
and, in fact, many of the laboratory tests come up the same for both. For example, one study 
conducted in 1957 showed that 28 of 83 patients (34%) with SLE had positive tests for rheuma­
toid factor which is usually characteristic for RA.9 Rheumatoid factor, specifically, is a type of 
autoantibody directed against immunoglobulins, mainly IgG; so, in other words, it is a type of 
antibody directed against other antibodies.8 It is present in approximately 75 to 80% of those 
with RA.7 But this overlap between diseases was shown in another study published in 1957 to 
occur in both directions. This study showed that of those with rheumatoid arthritis 27% (25 of 
91) had LE cells present. Another study showed that 17% of RA patients had LE cells in addi­
tion to symptoms like increased inflammation of the lung, enlargement of the spleen, uncharac­
teristic urinary specimens, and false-positive tests for syphilis. All of these symptoms seem much 
more indicative of SLE than RA. Physicians now believe that up to 10% of those with SLE have 
symptoms very similar to RA.9 Regardless of all the similarities, there are still ways to distinguish 
between the two diseases (as shown in Table 9). 
Discoid lupus erythematosus (DLE) often begins with the same cutaneous manifestations as 
SLE. A rash of scaly, red lesions occurs on the face, ears, and scalp in patients with DLE (see Fig­
ure 24). This is also the same type of rash seen in SLE. The two diseases can be fairly easily dis­
tinguished by the incidence of involvement of internal organs. DLE rarely affiicts any other 
organs other than the skin.ll It has been shown, however, that DLE can disseminate into full­
fledged SLE in some cases. One study showed that 20% of SLE patients in the study had DLE at 
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one time. In addition, of those with sub-acute SLE (lupus which has not fully disseminated) who 
were in the study, 26% had discoid lupus at one time. Some of the factors, thought to possibly 
cause these changes in lupus states, include the exposure to X-rays, UV radiation, certain antibi­
otics, and certain vaccines. There have also been some reports of patients who have reverted 
back to DLE from SLE after treatment.9 
"Drug-induced" lupus can also be misdiagnosed for SLE and vice versa. In fact, one study 
showed that about 10-12% of patients diagnosed with SLE actually had "drug-induced" lupus.' 
Many of the symptoms of "drug-induced" lupus are the same as those in SLE. Typical symp­
toms include fever, arthritis, and inflamma­
tion of the pleura and pericardium at about 
the same rate of occurrence as seen in 
SLE.ll In addition, some laboratory tests 
are similar in both "drug-induced" lupus 
and SLE. Specifically, tests for the presence 
of ANA show about the same rate of inci­
dence in both; anti-nRNP antibodies are 
also present in "drug-induced" lupus 
although in lower levels.' Anti-histone anti­
bodies found primarily in "drug-induced" 
lupus can occur in as many as 95% of 
patients with this affliction. 16 (Other tests 
which are positive in SLE such as for anti­
DNA and anti-Sm are negative in "drug­
induced" lupus, however.) 11 Other 
symptoms of "drug-induced" lupus (usually 
present in much lower percentages than in 
SLE) can occasionally include rash, anemia, 
swollen lymph glands, renal or gastrointesti­
nal problems, and emotional or mental dis­
turbances. One of the main distinguishing 
characteristics between the two diseases 
involves the distribution of groups primarily 
affected. As in SLE, the majority of cases of Figure 24. Characteristic lesions of discoid lupus in a 26­
"drug-induced" lupus are women, but not at year-old mall!. 
nearly as dramatic a difference as with 
SLE.' In addition, the ages normally affected between the two disorders differ greatly. The 
majority of patients with "drug-induced" lupus are either older people receiving treatment for 
irregular heartbeat and/or high blood pressure or children receiving drugs to control their 
convulsions. The medications used to treat these conditions are primarily to blame for causing 
"drug-induced" lupus, even though it can be caused by a variety of different drugs. These 
drugs include procainamide HCI (under the drug names Procan or Pronestyl) and hydralazine 
HCI (Apresoline) to treat hypertension, diphenylhydantoin or just phenytoin (Dilantin) to 
treat convulsions in epilepsy, isoniazid (Laniazid, Nydrazid, or Teebaconin) to treat tuberculo­
sis, penicillamine (Cuprimine or Depen Titratabs) to treat rheumatoid arthritis, and even the 
antibiotic tetracyline when it is unproperly stored.',l1 Most of the symptoms associated with 
"drug-induced" lupus generally disappear after the patient has been taken off the medication, 
but in up to 40% of cases the patient can continue to have these conditions for long periods of 
time (over six months).l1,1 
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SLE AS AN AurOIMMUNE DISFASE 
As with myasthenia gravis, experimentation with animals has provided most of the informa­
tion known about the mechanisms of SLE. It was very fortunate, therefore, that a type of mouse 
was found to have a naturally-occurring disease which is very similar to that of SLE. Discovered 
by three scientists in 1959, this mouse, named NZB - short for New Zealand black (referring to 
the place of origin and color of the mouse), develops autoimmune hemolytic anemia naturally 
(a condition which can occur in SLE). Later tests showed that this mouse also develops 
increased antibodies and renal dysfunction similar to that of lupus. But even more remarkable 
was the discovery that by crossing this mouse to a New Zealand white (NZW) mouse produced a 
disorder almost identical to that of SLE. (For example, the hybrid mice generally die from kid­
ney dysfunction, as in SLE, whereas the NZB strain develops lethal hemolytic anemia predomi­
nantly.) There are a couple of differences between the disorders, however. Firstly, the mice with 
this disease (both NZB and NZB/NZW) do not have any skin or joint problems at all. Secondly, 
all NZB mice, not just a few, become afflicted with this disorder, although some do so before 
others. But even with the differences, there is a very dose similarity between the two, especially 
when referring to the internal manifestations of both. Other aspects of these mice will be 
referred to at later times.7 
Origins ofthe Disease 
Mechanisms which make cause systemic lupus erythematosus are still widely unknown. There 
are, however, a broad range of theories which may explain this mystery. The first theory sug­
gests that a patient must have a genetic predisposition in order for SLE (and many other 
autoimmune diseases) to occur. This is no doubt the case in the NZB mice, for all mice develop 
this disease soon after birth. Researchers have also shown that this disorder is not passed from 
mother to fetus; an egg transplanted from a healthy mouse to a NZB mice will develop and be 
born as it would normally, without any of the signs of autoimmune disease. One of the many 
studies using humans researched a lupus patient and the patient's dose relatives to try to find 
some type of connection. What this study found was a broad range of unusual disorders affect­
ing these people. One of the patient's four sisters and a niece both had SLE. The patient's 
mother, two of four sisters, and a brother along with five nephews and a niece all had increased 
levels of antibodies in the blood. Another niece had evidence of rheumatoid factor and still 
another nephew had levels of both rheumatoid factor and other antibodies in the blood. These 
discoveries are far from common in normal populations.7 
Cases like the one above prompted scientists to look for a genetic mistake common to all SLE 
patients. Due to other discoveries correlating the occurrence of certain disorders and the pres­
ence of genetic factors found within the MHC region (which stands for major histocompatibility 
complex, so called because of the importance of this area in organ transplantation), researchers 
began searching this region for a common denominator. Found on the sixth chromosome of 
every human cell, the MHC region is different in everyone on earth except possibly identical 
twins. It is this region which codes for a number of antigens to be presented on the cell surface; 
these antigens allow the immune system to differentiate between an object which is part of the 
host and something which has invaded the body (so-called self and non-self). This region (also 
called the HLA region, for human leukocyte-associated antigen where it was first located) has 
been found to be made up of many different little subregions (or genetic markers as they are 
also known) which individually are responsible for producing a specific type of antigen or other 
gene product. It is this variability which gives each person their own unique immune system and 
is why there is such great difficulty in finding compatible donors for organ transplants.S After 
studying the MHC region for some time, researchers managed to locate a couple of possibilities 
within this area. There has been a higher incidence of subregions DRw2 and DRw3 and a some­
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what higher incidence of subregions Al and B8 being present within the HlA region of 
patients with SLE. (Figure 25 shows a map of the major histocompatiblity complex as seen in 
humans.) Specifically, a higher incidence of subregions DRw2 and DRw~ correlates to approxi­
mately 54% and 45% of SLE patients, respectively. In contrast, 26% and 20% of controls have 
also had these respective subregions. These figures are not startling, but they do present a basis 
from which further research can be conducted. Some researchers have theorized that these 
markers may work in concert with each other as well as individually. One study showed that 
almost 74% of SLE patients had either DRw2, DRw~, or both compared to 43% of controls. 
Another study showed that an AI-B8-DRw3 connection was present in ~5% of lupus patients 
compared to 16% of the controls. Again the differences are not that astounding? 
h----_______~L--_.__________________________________~'~I______________J~A 
Figure 25. Human Major HisliJcompatibilit, Complex 
There have been some connections made between types of markers present and the occur­
rence of other significant aspects of the disease, such as presence of certain types of antinuclear 
antibodies. One study found that in SLE patients with anti-Ro antibodies, 81% had the B8 mark­
er and 100% had the DRw3 marker. (Those without these antibodies had the B8 subregion 41 % 
of the time and the DRw3 subregion 25% of the time.) Another study found 70% of patients 
with anti-DNA an tibodies had the subregion DRw3 compared to 37% of those without these 
antibodies.7 There is no doubt that the occurrence of these genetic factors will be greatly 
researched in the future. 
Another important theory discussing the origin of SLE involves the possibility of viral (and 
somewhat less possible, environmental) influences in causing this disorder. Scientists and physi­
cians have long suspected that viruses may be the cause of certain autoimmune diseases includ­
ing lupus. Scientists have used two main methods to try to detect the presence ofviruses. As with 
the testing of all other suspected infectious agents, the first test is for the existence of antibodies 
specific for viral antigens, whereas the second simply involves the isolation of the organism. 
Although a specific virus has not been implicated yet, a variety of virally-associated products can 
be found in SLE. One study found antibodies produced against a group of viruses called 
reoviruses in 55% of those inflicted with SLE, compared to only ~% in the controls. Ret:roiruses 
have, on occasion, been found in some other illnesses, but nothing definite. Another group of 
viruses which has been determined to playa possible role in SLE are the paramyxt:roiruses, which 
include the viruses which cause measles, mumps, and rubella (also called German measles). Sev­
eral studies have shown high levels of antibodies to the mumps virus in large percentages of SLE 
patients.7 Other studies of SLE patients have shown high levels of antibodies to viruses such as 
the Epstein-Barr virus (a type of herpesvirus), the influenza B virus, and the Sendai virus (a rela­
tive of the mumps virus).17 Similar results have been seen in NZB and hybrid mice? 
As of yet, no one virus has been isolated from patients with SLE. There have been virally-asso­
ciated particles found within the nuclei of cells from afflicted patients, however. In the late 
1960s, Dr. Ferenc Gyorkey first found these particles in the tissues of a patient with SLE. He 
described the particles as being "myxoviruslike" and as being not entire viruses. (The myxovirus­
es are a class of viruses similar in nature to the paramyxoviruses; the root "myxo" comes from 
Greek meaning "mucus. It) These viral particles have primarily been isolated from the nerve 
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cells, skin cells, white blood cells, and kidneys of SLE patients, but have not been isolated from 
any person within the normal population, whatsoever.7 Although these particles were originally 
isolated from those with SLE, similar structures have now been found in a wide range of autoim­
mune diseases including hepatitis virus particles in autoimmune liver disease and retrovirus par­
ticles in Graves' disease (an autoimmune disease which primarily affects the thyroid gland) .19,20 
If these particles are derived from viruses which can cause autoimmune diseases, it is not 
understood how this occurs. During even the most severe disease activity, no viruses can be iso­
lated. It is thought that perhaps that the particles are the result of a persistent viral infection 
which remains dormant for long periods of time. This has been found to be true in a disease 
called subacute sclerosing panencephalitis or just SSPE. This disease, which is always fatal, 
affects the brain by degrading it along with all the other systems that the brain controls. SSPE, 
also known as Dawson's encephalitis, also contained particles which were "myxoviruslike." Later, 
scientists found that those afflicted had high levels of antibodies directed toward the measles 
virus. Finally in 1970, one researcher isolated the measles virus from a patient; it had apparently 
been present all along, but had been "lurking" within the tissues of the central nervous system 
and lymphatic system waiting for the proper time to reactivate.7 Whether this type of mecha­
nism also occurs in autoimmune disease is difficult to tell without further research, but there 
are signs that this may be how they occur. One experiment has shown that in both tissue cul­
tures and live animals viruses can lay dormant within cells for perhaps the entire lifetime of the 
animal, if certain conditions occur. This experiment showed that a virus called LCMV (lympho­
cytic choriomeningitis virus) when injected into a healthy animal will kill it due to an effective 
immune response against virus-infected host cells. But if the virus is injected into an animal 
which is either newly born or immunosuppressed (both of which have incomplete immune sys­
tems), the virus will remain inside of cells indefinitely, causing no harm except for inciting the 
formation of antigen-antibody complexes, a product which is common in SLE-mediated kidney 
disease.16 
There are many theories which try to explain how such a virus would cause an immune 
response to the host's own cells. Three of the main ones will be discussed here. Firstly, however, 
a little about how a virus usually infects cells must be explained. In a normal viral infection, the 
virus attaches itself to the host cell, penetrates into the cytoplasm (the internal fluid of the cell 
excluding the nucleus), and releases its genetic material which codes for its replication. After 
replication, the multiple copies of the virus now reassemble and leave the cell either by budding 
off of the cell or by rupturing the cell. One of the theories deals with what happens after repli­
cation. The author of this theory believes that something goes wrong with the host cells causing 
the virus to not be released. In fact, certain viruses require a specific enzyme to be present in 
the host cell, in order to become operational. Thus, if this enzyme is not present, then the virus 
would be "doomed" to remain within the host cell. Since an immune reaction occurs in 
response to any viral presence, the body produces antiviral antibodies which attack the only 
thing they can, the host cells where the virus is in hiding.7 
Another theory states that possibly the virus remains within the cell in a semi-dormant condi­
tion, inactive except for mechanisms which affect the host cell, so that the immune system no 
longer recognizes it as being "friendly". Instead the host cell is attacked as a foreign organism. The 
third theory also involves the belief that the virus tricks the immune system into believing the host 
cell is a foreign invader. This theory assumes that the genetic material from the virus splices itself 
into the host's genes (which in some cases it has been shown to do) where it begins to code its 
own proteins. These proteins then become incorporated into the host cell's membrane where 
they are perceived as being foreign by the immune system. The immune system then responds by 
producing antibodies against these foreign proteins, thus attacking its own cells.' 
The possibility of environmental factors as a cause of lupus has gained a great deal of atten­
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tion lately. Many scientists had discarded this belief as being nothing more than being a sec­
ondary possibility. But with the recent diagnosis of Graves' disease present in President Bush, 
environmental factors have jumped to the forefront ofautoimmune research. For in addition to 
the president, the First Lady, Barbara Bush, also has Graves' disease (she undeIWent treatment 
only one and a half years ago for this condition); even the dog Millie has a form of canine 
lupus. The odds of these events occurring naturally have been estimated at 20 million to one. 
Even so, most scientists still do not believe that there is a connection. One such scientist Uoshua 
Cohen of George Washington Medical Center) has said, "If I had to bet money, I'd bet that a 
specific factor linking these two cases isn't going to be found. It deserves careful thought, but it 
could be discovered they both just had a genetic susceptibility coincidentally." Vice-President 
Dan Quayle has not totally given up on such an idea, however. He seems to think that there are 
lead pipes in the Vice-Presidential mansion which have caused these autoimmune disorders in 
the Bushes while they lived there. Until there are a wide range of tests performed there will not 
be any concrete answers to this problem.!l 
The next theory involves the role of sex hormones in SLE. It has long been known that a 
large majority of SLE patients are women. This also occurs in many other autoimmune diseases 
like rheumatoid arthritis and myasthenia gravis. It has, therefore, been proposed that perhaps 
somehow estrogen acts as a type of accelerator and that the male hormones act like a kind of 
inhibitor of the disease. As was mentioned earlier, it is true that approximately 89% of those 
who get SLE are women, often around the age of 29. (If the reader remebers correctly, the aver­
age age of onset for men is 51.) In addition, before the menopausal age ofwomen the ratio of 
women to men who are amicted with this disorder is between 10 to 1 and 15 to 1. This ratio 
drops to 2 to 1 after the menopausal age (around 55). (Figure 9 printed earlier shows the 
change in proportions ofwomen to men with SLE, as it corresponds to age.) Furthermore, stud­
ies show that men who have the congenital disorder, Klinefelter's syndrome (this occurs when a 
male baby picks up an extra X chromosome, thus having an XXV pattern, instead of the normal 
XV pattern), are more likely to get SLE than other men. Those with Klinefelter's syndrome 
often have higher levels of female hormones and are usually sterile.7 
In addition, researchers have found that the removal of the testes along with the addition of 
male sex hormones tends to suppress disease activity, whereas removal of the ovaries along with 
replacement injections of female sex hormones makes the disease worse in most cases.16 One 
very interesting study supporting the importance of this discovery was published in 1975. This 
report described a pair of identical twins, who were forty-four at the time, in which only one had 
developed SLE. The other had, in fact, undergone treatment for ovarian cancer, where she had 
surgery to remove the both the ovaries and the uterus twenty-three years prior to the study (she 
did not receive any type of hormone injections to replace those lost by removal of these 
organs). Although both had false-positive tests for syphilis and the presence of high levels of 
antibodies, only the one with SLE had positive tests for LE cells and antinuclear antibodies. All 
other symptoms of SLE were absent in the woman who had undergone the surgery. So with this 
evidence, some researchers began to try to flng a direct correlation between sex hormones and 
autoimmune disease.' 
There have been no large scale studies so far, but there have been a variety of smaller studies 
performed to measure levels of sex hormones in SLE patients. One study of male SLE patients, 
performed to see whether male sex hormones (the androgens, as they are sometimes called) 
had some type of protective role in SLE, showed anything but promising results. Although some 
of the men did show occasional lower levels of certain hormones, the majority showed no 
change. What researchers did discover from such studies was that the metabolism of female sex 
hormones, which are also present in men in small levels, occurred differently in those with SLE 
than in normal patients. Estrone (a type of estrogenic hormone), normally broken down into 2­
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Hydroxyestrone, was instead metabolized into 16 alpha-hydroxyestrone as shown in figure 26. 
One study by Dr. Robert Lahita showed that in the normal patients this compound comprised 
only about 5% of the total metabolic products excreted in their urine, compared to almost 17% 
in male SLE patients and almost 21 % in female SLE patients.7 While scientists still do not know 
effects of sex hormones and their derivatives, activated by the presence of an outside force 
whether it is a virus or some type of environmental factor, all leading to the production of 
autoantibodies (antireceptor antibodies in the case of the figure) .16 
entiate and mature in the thymus (where the T comes from), can also be subdivided into four 
groups: the cytotoxic T cells (Tc) which recognize, bind to, and destroy foreign cells; the helper 
T cells (Th) which release substances to encourage an immune response; the delayed-type 
hypersensitivity T cells (Td) which secrete substances to influence other attack cells; and the 
the exact role of this metabolite 
in those who have SLE, they do 
know that this compound acts 
as a more powerful feminizer 
than those which are normally 
produced.16 
Whether any or all of the 
above possible causes of SLE 
and other autoimmune diseases 
are involved remains to be seen. 
But most researchers now feel 
that it is not just one of these 
factors, but possibly all of them 
as shown in figure 27. A person 
with such a disorder probably 
must have a genetic predisposi­
tion, accentuated later by the 
Physiological Mechanisms ofSLE 
While the theories expained 
above attempt to describe how 
autoimmune diseases begin, 
there are some definite changes 
within the body to help this to 
occur. These changes are espe­
cially seen within the specific sub­
groups of the white blood cells 
called lymphocytes. There are 
two main types of lymphocytes, 
the B cells and the T cells. The B 
cells, which originate in the bone 
marrow (thus, being partially 
responsible for the B in the 
name), are further subdivided 
into the general B cells and the 
plasma cells, which are sensitized 
B cells that secrete specific anti­
bodies. The T cells, which differ­
.. ..: 
Figure 26. Two pathways by which estradiol is metabolized. The 
metabolites from upper pathway are found in increased levels in 
patients with SLE. 
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Figure 27. Theory ofhow autoimmune diseases may arise. 
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suppressor T cells (Ts) which turns off an immune response to a foreign antigen.s In SLE, it 
appears that the suppressor T and plasma cells are affected the most. The suppressor T cell 
population in SLE appears to be greatly reduced for some reason. A couple of studies suggest 
that the suppressor T cells may be the target of autoantibodies directed against these cells and 
the precursor cells from which they are derived. In one study using tissue cultures, it has been 
shown that the blood serum from a patient with SLE can disrupt the normal maturation of pre­
cursor T cells to suppressor T cells in samples from normal individuals.7 This activity, therefore, 
would reduce the number of T cells available to regulate the action of the B cells. Suppressor T 
cells, specifically, block the transformation of antigen-sensitized B cells into antibody-secreting 
plasma cells. So if there was a lack of Ts cells, then plasma cells would theoretically be able to 
secrete antibodies indefinitely. Figure 28 shows this mechanism. There are a few problems with 
this theory, however. For one, in the NZB/NZW hybrid mice which were described earlier, their 
spleens tend to increase, and not decrease, the number of T cells which they secrete over time. 
In addition, immune responses to virally-infected cells still seem to occur normally. Lastly, a 
recent report has shown normal Band T cell functioning occurs in all ages of NZB/NZW mice 
(Le. activity does not wane with disease severity or with age). These actions should not occur if 
there is some type of suppressor T cell malfunction.16 This idea of suppressor T cell deficiency 
is still widely held by most scientists. 
Even more intriguing is the recent discovery that in SLE patients there is also a hyperactivity 
of B cells and plasma cells, above that which could be attributed to simple T cell deficiency. 
This study showed that there are eight to ten times more B cells in SLE patients than in normal 
individuals and that these B cells are unusually active.7 It has also been found that certain com­
pounds, such as lipopolysaccharide (compound which is found in certain cell membranes) 
shown in figure 29, act as B cell activators. These compounds cause plasma cells, even from nor­
mal individuals, to produce many different types of antibodies, including autoantibodies. It has 
been hypothesized that such an occurrence would overwhelm an already malfunctioning Ts cell 
population preventing a total suppression of this ac tivity. 1 6 
So how does all of this information add up to help one discover what causes SLE? The answer 
include all of the above factors. This author feels that it is possible that SLE may be activated by 
some type of foreign influence whether it is viral or environmental in a person who is already 
predisposed by genetic and hormonal factors (see Fig. 27 again). The foreign influence could 
possibly be the viruslike particles (which may be dormant viral genetic material) which have 
been found in many of the autoimmune diseases. These particles could act as activators to ele­
vate B cell activity to extremes. Such an action would thus cause these B cells (which would, in 
turn, differentiate into plasma cells) to produce autoantibodies to a wide range of tissue types 
including to the suppressor T cell and its precursor. Only once this occurs could SLE be fully 
active. 
TREATMENT AND FUfURE CURES 
Although there are no definite ways to remedy the problems of SLE, there are many different 
treatments directed at alleviating the symptoms. Treatments are often used depending on the 
severity of the present affliction. Due to the disease's irregular and insidious behavior, there is 
really no way to use preventive medicine in treating SLE. For many of the simple problems of 
SLE, NSAIDs are used. NSAIDs, which stands for nonsteroidal anti-inflammatory drugs, include 
many common medicines such as aspirin and ibuprofen. These drugs are most commonly used 
to treat simple aches and pains and a slight fever. They are also often used in the treatment of 
rheumatoid arthritis. Even with these simple drugs, however, there are some side effects. Some 
of these drugs have been found to occasionally cause high blood pressure, kidney dysfunction, 
and even some central nervous system problems. It must be understood that these side effects 
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Figure 28. Comparison ofnormal and abnormal suppressor T ceU function. Abnormal T ceU function would 
aUow plasma cells to produce autoantibodies indefinitely, resulting in immune complex formation . The for­
mation and depostion of these complexes are the primary way that the glomerular basement membrane of the 
kidneys is damaged. 
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Figure 29. B cell activation. The lipopolysaccharide stimulates B cells to the point that they begin to produce a 
wide variety of antibodies including autoantibodies suppressor T cells, even if working normally, would be 
overwhelmed. 
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are very rare in cases of SLE.7 However, many patients with SLE are "allergic" (in a sense) to 
these drugs and can have some adverse liver reactions due to this sensitivity. I I This phe­
nomenon can actually be quite common. One study showed that 35% of SLE patients had in 
the past some type of allergic reaction to drugs compared to only 20% of normal individuals. 
Most often, these SLE patients are sensitive to a variety of drugs largely because of their faulty 
immune systems. This presents something else a doctor must be careful of when treating a 
patient with lupus.' 
For the treatment of skin lesions, antimalarial drugs, especially quinine derivatives, are very 
useful. These drugs which include quinacrine (known by the drug name, Atabrine), chloro­
quine (Aralen), and hydroxychloroquine (Plaquenil) have been used less often in recent times. 
One of the reasons for this is that there have been many side effects associated with this group 
of drugs. Damage to the eye is, perhaps, the side effect of greatest concern. This damage can 
range from a temporary 
blurriness to permanent 
blindness.' Instead of using 
an timalarial drugs, many 
physicians have opted to 
use topical corticosteroids 
which have very few side 
effects. A topical corticos­
teroid cream applied to skin 
lesions can help clear up 
these symptoms in both 
SLE and DLE.ll 
Physician s most often Figure 30. X-ray showing osteonecrosis of the femoral head at the right. 
prescribe general corticos­
teroids, such as prednisone, when symptoms become more severe. These drugs can be used in 
either low doses for long periods of time or in extremely high doses if the conditions are severe 
enough. It is thought that corticosteroids act by inhibiting the secretion of antibodies and may 
also inhibit the response of helper T cells which were discussed in the last section.' Physicians 
often use corticosteroids to treat a wide range of conditions including kidney and eNS involve­
ment. One problem with the use of corticosteroids for the treatment of SLE involves the many 
side effects which occur as a result. Side effects can include acne, abnormal hairiness, fluid 
retention and weight gain, high blood pressure, skin rash and streaks, muscle disease, cataracts, 
and disrupted sugar metabolism.22 Other side effects can include susceptibility to infection, 
stomach ulcers, delayed healing time after injuries, increased the possibilities for diabetes, and, 
less often, emotional disturbances.' The emotional problems may be due to the wide range of 
other side effects which are occurring. What young woman would not be disturbed by abnormal 
growth of hair on the body and enormous weight gain (up to as much as 60 to 80 pounds), in 
addition to all the other conditions caused by both the disease and the drug treatment. So often 
depression sets in as a result. ll 
Large doses of drugs in treatment can also be very debilitating later in life. Many patients 
who have received large doses at one time or another often develop osteoporosis (readsorption 
of bone by the rest of the body), osteonecrosis (death of bone cells, often associated with bone 
disintegration - an example of this is shown in Figure 30), and atherosclerosis (blockage of 
blood vessels by plaques containing cholesterol). Two studies by autopsy have shown that almost 
one-half of those SLE patients, who had at one time or another received high doses of corticos­
teroids, had at least one coronary artery three-fourths of the way blocked by plaques. This has 
also been found to occur in smaller amounts in patients who receive low doses of drugs. This 
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seems to occur because of increased levels of cholesterol in the blood caused by these drugs.22 
The next group of drugs which are used for SLE treatment are the immunosuppressants. 
These drugs are used in only dire situations because they are so potent. The two main drugs of 
this group are azathioprine, which acts by inhibiting cell growth (cytostatic), and cyclophos­
phamide, which acts by killing certain cells (cytotoxic). These drugs are mainly directed at stop­
ping the growth of the rapidly proliferating B cells, as was described earlier. The only problem 
with these drugs is that they not only attack the B cells which produce the autoantibodies, but 
also the B cells which help fight off other infections. As a result, a patient who undergoes treat­
ment using these drugs are extremely susceptible to infection of any kind.7 The most common 
type of infection is by herpes zoster viruses which cause inflammation of the cerebral nerves. 
Herpes zoster is the virus which causes chickenpox, but afterward it often remains in nervous 
tissue until it becomes reactivated. Other side effects caused by these drugs, as shown in Table 
10, are largely due to the cytostatic and cytotoxic actions of these drugs on other growing cells. 
Because of the many severe side effects, these drugs are falling out of favor with physicians.22 
There are other methods used to treat SLE, but these are not as widely used as that of drug­
therapy. These treatments are more of a physical nature as opposed to a chemical one. Surgery 
is occasionally performed by physicians in order to treat some of the conditions associated with 
SLE. Splenectomy is the most common surgical procedure; it is often used to alleviate the 
hemolytic anemia which is often a disorder seen in SLE. There are few side effects caused by 
this procedure, mainly because the liver and the lymph nodes assume the normal responsibili­
ties of the spleen.7 The benefits of this procedure are not totally clear, however. For this reason, 
many physicians do not recommend this procedure. 
In the case of kidney failure, a patien t usually first begins a procedure called dialysis where 
an external machine filters the blood of the patient. Occasionally, the kidneys will respond and 
begin performing normally again. Studies have shown that about thirty to forty percent of 
patients regain normal kidney function after dialysis. If this does not occur, then kidney trans­
plant is the next option. With recent strides made in the area of organ transplantation, physi­
cians can transplant a new kidney with great success. Normal function of the transplanted 
kidney over a five year period continues in about 75% ofpatients.7 
One of the last methods of treatment is plasmapheresis as was discussed in the section on 
treatment of myasthenia gravis. This procedure simply removes a large portion of autoantibod­
ies which are present in the blood. But due to varying reports on its success and great cost of the 
procedure, plasmapheresis is rarely used.7 
There are relatively few prospects at the present time for the complete cure of patients with 
SLE. There are two types of treatments which are being tested now which may become possible 
cures in the future. One of these involves bone marrow transplantation. Extensive clinical tests 
in mice show that if bone marrow, taken from a healthy mouse with no signs or history of 
autoimmune disease whatsoever, is transplanted into one of the NZB mice, then the NZB 
mouse will begin to get better until it no longer has any symptoms of autoimmune disease. Most 
researchers believe that this technique manages to cure all the disorders within the NZB mouse 
by presenting genetic material essential to the normal functioning of the mouse's immune sys­
tem. Further tests will need to be conducted to see how effective this type of treatment is in 
7humans and what side effects, ifany, it causes.
The other method of treatment is called total lymphoid irradiation (TLI). This technique, 
which is really just a way to handle the malfunctioning immune system, involves the exposure of 
the patient's lympatic system (which includes the lymph nodes and spleen) to high doses of 
radiation. Exposure is limited to only the lymphatic system by the use of large lead plates to pro­
tect the other tissues. Doses much larger than that which would normally kill a human being 
can be used by splitting up the treatment into about four sessions per week until the total 
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dosage is reached. This technique, which is already used in humans for the treatment of other 
disorders, uses dosages of about 200 rad per session. Whereas humans can not normally survive 
a single dose of radiation over 400 rad, this technique amasses dosages of over 4,000 rad over a 
period of time. 
TLI seems to be most beneficial in suppressing unnecessary immune responses, while still 
allowing reactions to foreign invaders. It is currently being used to treat Hodgkin's disease (a 
potentially fatal disorder where the lymphatic tissues all over the body enlarge in enormous 
amounts) and immune responses from organ transplantation. In addition, it has been shown to 
be very helpful in treating disorders in NZB mice and in other animals with autoimmune dis­
eases. Another promising discovery is that TLI has been found to have relatively few side effects 
associated along with it. Some of the common side effects include diarrhea, general weakness, 
loss of appetite, and abdominal cramps. Other less common side effects are herpes zoster infec­
tion (in about 30% of 
patients), thyroid abnormal­
'Wallace et al (1981)ities (in about 20% of I 00 ''"'''".--.." ..... 
patien ts), bone marrow 
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So what can a person 	 10 
Years 
with SLE expect out of his 
or her life in the future? 
Figure 31. Various studies ofsurvival rates of those with SLEWell, although there are 
some new types of treat­
ment being tested now, a cure for SLE does not appear to be any time soon. Even so, a person 
with SLE can live a fairly normal life, for this disease is no longer a death sentence as it was at 
one time. Survival rates have increased remarkably over the past few years, partially due to the 
increased use of drugs in treatment and partially due to better methods for the detection of 
SLE (i.e. ANA tests). Less than 40 years ago, the chances of living for five years after SLE was 
diagnosed were less than 40%. In addition, death within one year after diagnosis was rather 
common.7 But in the present, those with SLE have over an 80% chance of surviving at least ten 
years.22 (Figure 31 shows a graph mapping the changes in survivorship as reported in various 
studies over the past thirty years.) So what can an SLE patient expect? This person should 
expect to live for many years to come. And as future treatments surpass those of today, such a 
person will be able to live a normal life with very few problems. So it is in the patient's best inter­
est to keep an optimistic outlook of his or her affliction because things will only get better. 
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CLOSING REMARKS 
The realm of autoimmune disease has much left to be explored. But before scientists can 
attempt to contemplate the real mechanisms of these diseases, there must first be an attempt to 
try to understand the immune system itself much better and all the interactions between the 
cells which make up this system. Once this is achieved only then will real advances be made in 
the area of autoimmunity. 
For the reader, hopefully this has presented some insight into autoimmune diseases. It was 
meant to give the reader some understanding of what these people are going through. For the 
reader who is afflicted with one of these diseases, it must be understood that these diseases are 
not necessarily fatal; they are simply conditions which are chronic. And do not worry if you have 
just been diagnosed, for the day will come when medical science has caught up to these disor­
ders. One just has to be patient. It is not that far away. 
TABLES 
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Table 1 
SIDE EFFECfS OF ANTICHOLINESTERASE DRUGS(2) 
On Muscarinic Receptors (involve smooth and cardiac muscle and glandular tissue) 
Dizziness &: Jitters 
Mental Confusion 
Nausea &: Vomiting 
Abdominal Cramps &: Diarrhea 
Urinary Frequency 
Bronchospasm (contraction of the walls of the bronchi) 
Hypotension (lowered blood pressure) 
Bradycardia (abnormal slowness of the heart beat) 
Increased Salivation 
Sweating 
On Nicotinic Receptors (involve skeletal muscle and ganglion cells) 
Fasciculations (small local contraclions of muscles) 
Muscular Weakness 
Fatigability 
SIDE EFFECTS OF STEROIDS (AS IMMUNOSUPPRESSANTS) 
Acne 

Hypertension (increased blood pressure) 

Edema (accumulation offluid in tissues) 

Gastrointestinal Irritation 

Hypokalemia (abnormally low potassium content in blood) 

Growth Suppression in Children 

Susceptibilty to Infection 

SIDE EFFECTS OF OTHER IMMUNOSUPPRESSANTS 
Nausea &: Vomiting 

Pancreatitis (inflammation of 

Esophagitis these organs) 

Ascites (effusion of serous fluid into the abdominal cavity) 

Mouth Ulcers 

Bone Marrow Depression 

Leukopenia (reduction in number of leukocytes) 

Anemia (reduction in number of erythrocytes) 

Thrombocytopenia (decrease in number of blood platelets) 

Hepatotoxicity (poisonous effect on liver 

Nephrotoxicity and kidney, respectively) 

Alopecia (loss of hair) 
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Table 2 
CRISIS SYMPTOMS2 
Symptoms of both myasthenic and cholinergic crises 
1. Severe muscular weakness involving generalized muscles and 
those necessary for breathing, chewing, speaking, and swallowing 
2. Apprehension and restlessness 
3. Increased bronchial secretions, sweating, salivation, and 
lacrimation 
Distinguishing symptoms of a myasthenic crisis 
1. Positive response to the Tensilon test 
2. Increased pulse rate 
3. Absence of cough and gag reflexes 
Distinguishing symptoms of a cholinergic crisis 
1. Negative response to the Tensilon test 
2. Nausea and vomiting 
3. Diarrhea and abdominal cramps 
4. Diplopia 
5. Bradycardia and hypotension 
6. Fasciculations 
7. Onset 15 to 45 after an anticholinergic medication is taken 
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Table 3 
INCORRECT DIAGNOSES IN THOSE lATER FOUND TO HAVE LUPUS9 
Acute nephritis (inflammation of the kidney) 
Acute psychosis (prolonged behavioral disorders) 
Acute rheumatic fever 
Brucellosis (infection caused by one of the species of Brucella) 
Cerebral vascular accident (copious extravasation· discharge - of 
blood within the brain) 
Dermatomyositis (inflammation of the skin, subcutaneous tissue, 
and underlying muscle) 
Drug reaction 
Epilepsy 
Erythema multiforme (complex characterized by numbers ofvarious 
types of lesions which appear suddenly) 
Felty's syndrome (comb. of chronic arthritis, enlargement of spleen, 
reduction ofleukocytes, and spots on lhe skin) 
F ever ofunknown origin 
Lymphoma (cancer of the lymph nodes) 
Meningitis (inflammation of the meninges - membranes surrounding 
the brain and the spinal cord) 
Nephrosis (any disease of the kidney) 
Peripheral neuritis (inflammation of the nerve endings) 
Pleurisy (inflammation of the pleura - membrane lining the lungs 
and thoracic cavity) 
Pneumonia 
Polyarteritis (inflammation of several arteries at the same time) 
Purpura (condition characterized by pinpoint, purplish red spots) 
Raynaud's phenomenon (paling and numbing of fingers or toes) 7 
Rheumatoid arthritis 
Scleroderma (autoimmune disorder characterized by hardening and 
leather-like appearance of the skin) 7 
Septicemia (presence in the blood of bacterial toxins) 
Subacute bacterial endocarditis (inflammation of the lining of the 
heart caused by bacteria) 
Syphilis 
Trichinosis 
Tuberculosis 
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Table 4 

PREUMINARYCRITERIA FOR THE ClASSIFICATION OF SLE (1971 ed.) 

1. Facial erythema: Diffuse erythema, flat or raised. over the malar 
eminence(s) and/or bridge of the nose; may be unilateral 
(butterfly rash) 
2. Discoid lupus: Erythematous raised patches with adherent 
keratotic scaling and follicular plugging; atrophic 
scarring may occur in older lesions; may be present 
anywhere on the body 
3. Raynaud's phenomenon: Requires tw~phase color reaction, by 
patient's history or physician's observation (see Fig. 21) 
4. Alopecia: Rapid loss of large amount of the scalp hair, by 
patient's history or physician's observation 
5. Photosensitivity: Unusual skin reaction from exposure to sunlight 
by patient's history or physician's observation 
6. Oral or nasopharyngeal ulceration 
7. Arthritis without deformity: One or more peripheral joints 
involved with any of the following in the absence of 
deformity: (a) pain on motion; (b) tenderness; 
(c) effusion or periarticular soft tissue swelling 
8. LE cells: Two or more classical LE cells seen on one occasion or 
one cell seen on two or more occasions, using an 
accepted published method 
9. Chronic false-positive serologic test for syphilis: Known to be 
present for at least 6 months and confirmed by 
Treponema pallidum immobilizing or Reiter's tests 
10. Profuse proteinuria: Greater than 3.5 gm/day 
11. Cellular casts: May be red cell. hemoglobin, granular, tubular, or 
mixed 
12. One or both of the following: (a) Pleuritis, convincing history of 
pleuritic pain; or rub heard by a physician; 
roentgenographic evidence of both pleural thickening and 
fluid; (b) pericarditis, documented by electrocardiogram 
or rub 
13. One of the following: (a) Psychosis; (b) convulsions, by patient's 
history or physician's observation in the absence of uremia and offending drugs 
38 
14. One or more of the following (a) Hemolytic anemia; 
(b) leukopenia: on two or more occasions, white blood 

cell count less than 4,OOO/mm"3; (c) thrombocytopenia, 

platelet count less than IOO,OOO/mm"3 
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Table 5 
1982 REVISED CRITERIA FOR CLASSIFICATION OF SLE12 
1. Malar rash: Fixed erythema, flat or raised, over the malar 
eminences, tending to spare the nasolabial folds 
2. Discoid rash: Erythematous raised patches with adherent 
keratotic scaling and follicular plugging; atrophic 
scarring may occur in older lesions 
3. Photosensitivity: Skin rash as a result of unusual reaction to 
sunlight, by patient history or physician observation 
4. Oral ulcers: Oral or nasopharyngeal ulceration, usually painless, 
observed by a physician 
5. Arthritis: Nonerosive arthritis involving 2 or more peripheral 
joints, characterized by tenderness, swelling, effusion 
6. Serositis: (a) Pleuritis: convincing history of pleuritic pain or 
rub heard by a physician or evidence of pleural effusion; 
(b) Pericarditis: documented by ECG or ru b or evidence 

of pericardial effusion 

7. Renal disorder: (a) Persistent proteinuria greater than 0.5 grams 
per day or greater than 3+ if quantitation not performed; 
(b) Cellular casts - may be red cell, hemoglobin, 

granular, tubular, or mixed 

8. Neurologic disorder: Seizures - in the absence of offending drugs 
or known metabolic derangements; e.g., uremia, 
ketoacidosis, or electrolyte imbalance; (b) Psychosis-
in the absence of offending drugs or known metabolic 
derangements (see above) 
9. Hematologic disorder: (a) Hemolytic anemia: with reticulocytosis 
(b) Leukopenia -less than 4,000/mmI\3 total on 2 or 

more occasions (c) Lymphopenia -less than 1,500/mmI\3 

on 2 or more occasions; (d) Thrombocytopenia - less 

than 100,000/mmI\3 in the absence of offending drugs 

10. Immunologic disorder: (a) Positive LE cell preparation; (b) Anti­
DNA: antibody to native DNA in abnormal titer; (c) Anti-
Sm : presence of antibody to Sm nuclear antigen; 
(d) False positive serologic test for syphilis known to be 

positive for at least 6 months and confirmed by 

Treponema pallidum immobilization or fluorescent 

treponemal antibody absorption test 
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11. Antinuclear antibody: An abnormal titer ofantinuclear antibody 
by immunofluorescence or an equivalent assay at any 
point in time and the absence of drugs known to be 
associated with "drug-induced" lupus syndrome 
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Table 6 
AUTOANTIBODIES IN NORMAL POPUlATIONS 
Species Autoantibodies (AA) 
Man 
Mouse 
Rat 
Rabbit 
Calf 
Pig 
Anti-lymphocyte AA 
An ti-tu bulin AA 
Anti-nuclear AA 
Anti-smooth muscle AA 
Anti-double-stranded RNA AA 
Anti-lymphocyte AA 
Anti-nucleoprotein AA 
Anti-IgGAA 
Anti-lymphocyte AA 
Anti-tubulin AA 
Anti-tubulin AA 
Anti-tubulin AA 
definitions for those listed above are in the glossary, all information from reference #17 
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Table 7 
DEFINED ANTIGEN SPECIFICITIES 
Antibody to: 
Nucleic Acid Ag 
Deoxynucleoprotein (anti-DNP) 
Deoxyribonucleic acid 
(anti-DNA) 
single-stTanded DNA 

double-stTanckd DNA 

Ribonucleic acid (anti-RNA) 
Nucleolar RNA (4-6s RNA) 
Histones (anti-histone) 
Non-Histone Nuclear Protein Ags. 
Smith (anti-Sm) 

Ribonucleoprotein 

(anti-nRNP) 

Sjogren's Syndrome A 

(anti-SS-A & anti-Ro) 

Sjogren's Syndrome B 

(anti-SS-B, anti-La, & anti-Ha) 
MA-l (anti-MA-l) 
Scleroderma 70 (ScI-70) 
Prolif. cell nuclear Ag (anti-PCNA) 
Ab to Other Ags. 
Chromo centromere (ACA) 
Mitotic spindle apparatus 
(anti-MSA) 

Nuclear matrix 

Mi-l (anti-Mi-l ) 

Jo-l (anti:Jo-l) 

Ku (anti-Ku) 

PM-l (anti-PM-l) 

SL (anti-SL) 

Rheumatoid Arthritis 

nuclear Ag (anti-RANA) 
Cytoplasmic An tigens 
Actin (an ti-actin) 
Golgi apparatus (anti-Golgi) 
Lysosomes (anti-lysosomes) 
Mitochondria (anti-mitochondrial) 
Ribosomes (anti-ribosomal) 
Incidence: 
70% in SLE 16 
mainly SLE, low levels in chronic active 
hepatitis,JCP, some normal population 
70-80% in SLE 7 
90% in SLE 7 
40-80% in SLE 17 
40-50% in PSS 16 
30% in SLE, 90% in "drug-induced" lupus 
only 30% in SLE, non-existent in others 
95-100% in MCTD,16 40-45% in SLE, 
20% in "drug-induced" lupus7 
70% in Sjogren's Syndrome,16 
some with SLE (30-40%)17 
60% in Sjogren's Syndrome,16 
20% in SLE 
only in SLE (20%) 17 
15-30% in PSS 
less than 10% in SLE 
80-90% in CREST scleroderma 16 
variety of connective tissue disorders 
rare, found in 0.05% w/ANA 
in MCTD & those w /anti-nRNP 
first found in dermatomyositis (% unknown) 
in polymyositis (30%), dermatomyositis (rare) 
55% in both polymyositis & scler., rare alone 
specific only for polymyositis (55%) 
seen in those with both SLE & SS 
high levels (85-95%)16 in those with RA, 
lower levels in other diseases 
found in chronic active hepatitis 
found in SS & SLE 
60-70% in SLE 17 
20% in SLE 17 
15-20% in SLE 17 
antigen abbreviations are arbitrarily designated; unless otherwise noted info. from ref. #12 
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Table 8 
OTHER AUTOANTIBODIES IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS 
Autoantibodies (AA) Incidence 
Rheumatoid Factor 
Anti-erythrocyte AA 
Anti-platelet AA 
Anti-Iympho/thymocyte AA 
Anti-cardiolipin AA 
An ti-liver AA 
Anti-kidney AA 
An ti-thyroid AA 
Anti-neuronal AA 
An ti-collagen AA 
30% 
10-40% 
40-80% 
70-80% 
20% 
<5% 
<5% 
10-25% 
10-30% 
<5% 
definitions of the above tissue types are in the glossary. all information from reference #17 
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Table 9 
DIFFERENTIAL DIAGNOSIS BETWEEN SLE AND RAll 
Factors 
Joint Pain 
Anemia 
Rheumatoid 
Factor 
Facial Rash 
Sensitivity 
Mouth Ulcers 
Alopecia 
Fever 
Kidney Probs. 
ANA Positive 
False-positive 
syphilis test 
Anti-DNAAb 
SLE 
Present, usually without 
objective signs 
May be present 
Sometimes positive 
Frequent 
Frequent 
Occasional 
Frequent 
Frequent. very high 
Often present 
Sometimes positive 
Occasional 
Usually positive 
..M. 
Present, with swelling 
and perhaps later X-ray changes 
May be present 
Usually positive 
Non-existen t 
Rare 
Non-existent 
Rare 
Usually low when 
present 
Not present 
Almost never 
Negative 
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Table 10 
POTENTIAL SIDE EFFECTS OF CYCLOPHOSPHAMIDE & AZATHIOPRINE 22 
Cyclophosphamide Azathioprine 
Common (more than 10% ofpatients) 
Gastroin testinal + + 
Bone marrow suppression + + 
Suppressed immunity + + 
Alopecia + 
Gonadal su ppression + 
Hemorrhaging within + 
bladder 
Uncommon 
Cancer + + 
Bladder cancer + 
Hypersensitivity reactions + 
Fibrous tissue formation + 
within bladder 
Urinary problems + 
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ABBREVIATIONS AND ACRONYMS 

Ab antibody 
ACA. antibody to chromosomal 
centromere 
ACh acetylcholine 
AChR acetylcholine receptor 
Ag antigen 
ANA antinuclear antibody 
ARA American Rheumatism 
Association 
CNS central nervous system 
CREST calcinosis, Raynaud's 
phenomenon, esophageal 
dysfunction, sclerodactyly, 
telangiectasia 
C3 complement component #3 
C9 complement component #9 
DLE discoid lupus erythematosus 
DNA deoxyribonucleic acid 
DNP deoxyribonucleoprotein 
EAMG experimental autoimmune 
myasthenia gravis 
HIA human leukocyte-associated 
(antigen) 
Ig immunoglobulin 
IgG immunoglobulin G 
JCP juvenile chronic 
polyarthri tis 
LCMV lymphocytic 
choriomeningitis virus 
MCrD mixed connective tissue 
disease 
MG myasthenia gravis 
MHC major histocompatibility 
complex 
MSA mitotic spindle apparatus 
nRNP nuclear 
ribonucleoprotein 
NSAID nonsteroidal 
anti-inflammatory drug 
PCNA proliferating cell nuclear 
antigen 
PMN polymorphonuclear 
(leukocyte ) 
PSS progressive systemic 
sclerosis 
RA rheumatoid arthritis 
RANA rheumatoid arthritis 
nuclear antigen 
RNA ribonucleic acid 
SLE systemic lupus 
erythematosus 
SS Sjogren's syndrome 
SSPE subacute sclerosing 
panencephalitis 
Tc cytotoxic T (cell) 
Td delayed-type hypersensitivity 
T (cell) 
Th helper T (cell) 
TU total lymphoid irradiation 
Ts suppressor T (cell) 
47 
GLOSSARY 
Acetylcholine. a neurotransmitter found in many of the neuromuscular junctions of the body. 
Actin· a protein found in muscles. It is very important in contraction. 
Action Potential- the electrical activity developed in a muscle, nerve or the central nervous sys­
tem during activity. 
Albwnin - a group ofwater-soluble proteins found in animal tissues. 
Alopecia - a general loss of hair. 
Anasarca - generalized swelling throughout the entire body. 
Androgen - a male sex hormone. 
Anemia - reduction in the number of red blood cells. 
Antibody - serum protein formed in response to an antigen not recognized by the immune sys­
tem. 
Antigen - any foreign material which can be specifically bound by antibody or T cell receptors. 
Antinuclear Antibody - an antibody produced against nuclear material (DNA, RNA, etc.) of any 
kind. 
Aphasia - defect in the power of speech, writing, or signs, or of comprehending spoken or writ­
ten language. 
Ascites - the effusion of serous fluid into the abdominal cavity. 
Atherosclerosis - the blockage of blood vessels by cholesterol-containing plaques. 
Autoantibody - antibody produced against one's own tissues. 
Autoimmunity- immune response to one's own tissues. 
Axillary Lymph Nodes - the lymph nodes found underneath the arms. 
B Cell- a type of lymphocyte which originates and differentiates in the bone marrow of an indi­
vidual. 
Bradycardia - abnormal slowness of the heartbeat. 
Bronchospasm. rapid contraction of the walls of the bronchi. 
Bronchus· a branch of the trachea within the lung. 
Brucellosis· infection caused by one of the species of Brucella. 
Calcinosis - a condition characterized by formation of calcium deposits in certain tissues. 
Cardiac Rub - another term for a heart murmur. 
Cardiolipin - a substance which is present in the heart. 
Cellular Cast - a complex of protein and different cells types, depending on the cast, which is 
similar in shape to a kidney tubule. 
Central Nervous System - the part of the nervous system including the brain and the spinal 
cord. 
Cerebral Vascular Accident - a copious extravasation (discharge) of blood with the brain. 
Cervical Lymph Nodes - the lymph nodes found in the neck. 
Cholinergic Crisis - an overdose ofanticholinesterase drugs, seen in patients with myasthenia 
gravis. 
Cholinesterase - a membrane-bound enzyme which degrades acetylcholine. 
Chromosomal Centromere - the region where the arms of the chromosome meet. 
Colon - part of the large intestine. 
Complement. a lytic substance in normal serum that combines which an antibody-antigen com­
plex, producing lysis when the antigen is an intact cell. There are nine known components of 
complement. 
Corticosteroids - a type of steroid produced in the adrenal gland (located near the kidneys) 
often used to suppress the immune system in autoimmune diseases or in organ transplantation. 
Cutaneous - referring to skin. 
Cytoplasm - the fluid ofa cell not including the nucleus. 
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cytostatic - that which inhibits cell growth. 

Cytotoxic - that which kills certain cells. 

Cytotoxic T Cell- a type ofT cell which recognizes, binds, and destroys foreign cells. 

Delayed-Type Hypersensitivity T Cell .. a type ofT cell which secretes substances to influence 

other attack cells. 

Deoxynucleoprotein .. DNA with proteins attached to it. 

Dennatomyositis - inflammation of the skin, subcutaneous tissue, and underlying muscle. 

Diplopia - double-vision. 

Discoid Lesions - disk-like lesions characterized by elevated, reddish patches of rough and scaly 

skin. 

Discoid Lupus ErythematoSWI - an autoimmune disease which affects only the skin of patients. It 

is somewhat similar to systemic lupus erythematosus. 

"Drug-Induced" Lupus Erythematosus .. a condition which appears after the use of certain drugs 

and has many of the same symptoms as systemic lupus erythematosus. 

Dypsnea - difficult or labored breathing. 

Edema - the accumulation of fluids within tissues. 

Electrocardiogram .. a graphic tracing of the electrical current produced by contraction of the 

heart muscle. 

Electrolyte .. a solution which conducts electricity by means of its ions. 

Electromyogram .. the record of changes in the electrical activity of a muscle. 

Endocarditis .. inflammation of the endocardium. 

Endocardium .. the internal lining of the heart. 

Endocytosis .. the inclusion of certain particles into the cell. 

Enzyme .. a protein complex which speeds up chemical reactions. 

Epstein-Barr Virus .. a type of herpesvirus which is responsible for a disorder called Burkitt's lym­

phoma (a transformation ofB cells resulting in tumors). 

Erythema .. redness of the skin caused by the congestion of underlying capillaries. 

Erythema Multiforme .. a complex characterized by numbers ofvarious types oflesions which 

appear suddenly. 

Erythrocyte - a red blood cell. 

Esophageal .. reffering to the esophagus. 

Esophagitis .. inflammation of the esophagus. 

Estrone .. a type of estrogenic hormone. 

Fasciculation .. a small local contraction of muscles. 

Felty's Syndrome - a condition characterized by a combination of chronic arthritis, enlargement 

of the spleen. reduction in leukocytes. and spots on the skin. 

Fibrin .. an insoluble protein which is responsible for the essential portion of a blood clot. 

Fibrous Tissue - tissue having many fibers which often grows between other layers of tissue. 

Follicular Plugging .. the blockage of hair follicles. 

Germinal Center .. area in lymphoid tissue where the formation and differentiation of lympho­

cytes occurs. 

Golgi Apparatus .. a complex network in the cell's cytoplasm believed to be important in secre­

tion of cellular substances. 

Graves' Disease .. an autoimmune disease which primarily affects the thyroid gland. 

Heart Murmur .. a gentle blowing sound heard during heartbeats upon direct examination of 

the chest. 

Helper T Cell- a type ofT cell which releases substances to encourage an immune response. 

Hemoptysis .. bloody sputum 

Hepatomegaly .. enlargement of the liver. 
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Hepatotoxicity - a poisonous effect on the liver. 
Herpes Zoster - the type ofvirus which produces chickenpox and shingles. 
Histocompatibility - Being matched in regard to organ transplantation. 
Histone - a group of proteins which are often complexed with DNA. 
Hypetplasia - abnormal growth of normal cells. 
Hypertension - increased blood pressure. 
Hypoalbuminemia - abnormally low albumin content in the blood. 
Hypokalemia - abnormally low potassium content in the blood. 
Hypotension -lowered blood pressure. 
Ileum - part of the small intestine. 
hnmwtofluoresence Assay - a technique which uses fluorescently-tagged antibodies for the 
detection of certain antigens. 
Immwtoglobulins - serum protein, produced by certain white blood cells, which specifically 
binds to an antigen. The proteins called antibodies are included in this group. 
Juvenile Chronic Polyarthritis - a disorder which is very similar to rheumatoid arthritis. Also 
called juvenile rheumatoid arthritis. 
Keratotic Scaling - formation of hard calluses on the skin. 
Ketoacidosis - an accumulation of keto acids (chemical compound with a CO group and a 
COOH group in it) in the blood. 
Klinefelter's Syndrome - a congenital disorder which occurs when a male baby picks up an extra 
X chromosome, thus having an XXVpattern, instead of the normal XYpattern. 
Lacrimation - increased secretion of tears. 
Leukocyte - a general term for a white blood cell. 
Leukopenia - reduction in the number ofwhite blood cells. 
Lipopolysaccharide - a compound found in certain bacterail cell membranes which can pro­
duce an inflammatory response. 
"Lupoid Hepatitis" - a condition characterized by the presence ofLE cells, antinuclear antibod­
ies, and active liver disease. 
Lupus Profwtdus - a condition which occurs as deep lesions within the skin appearing as hard­
ened lumps. 
Lymphocyte - a type ofwhite blood cell responsible for controlling many of the immune 
responses. 
Lymphocytic Choriomenigitis Virus . a type of virus which have been found to be able to pro­
duce a persistent infection because of its becoming dormant 
Lymphoma - cancer of the lymph nodes. 
Lymphopenia - a reduction in the number of lymphocytes. 
Lysosome - a cytoplasmic vacuole which contains many different types of enzymes for the diges­
tion of material which is engulfed into the cell. 
Maculopapular - referring to small, elevated bumps, which are often discolored when compared 
to other areas. 
Malaise - a condition of general body discomfort 
Malar Eminence - another term for the cheek bones. 
Membrane Depolarization - the act of transmission of an electric current down a nerve cell or a 
muscle. 
Meninges - the membranes surrounding the brain and the spinal cord. 
Meningism - a hysterical simulation of meningitis. 
Meningitis - inflammation of the meninges. 
Mitochondria - a complex which is responsible for cellular metabolism. 
Mitotic Spindle Apparatus - the compound which is responsible for separating the chromo­
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somes during mitosis. 

Mixed Connective TISSue Disease· an autoimmune disease which is actually a combination of 

many different types ofautoimmune disease, as a result symptoms are wide-ranging. It is also 

called the "overlap syndrome. JJ 

Monoclonal Antibody - an antibody which is produced by a clone ofa specific plasma cell 

Myalgia - the aching of muscles. 

Myasthenic Crisis - an adverse reaction to a removal from or a change of medication, seen in 

patients with myasthenia gravis. 

Myocarditis - inflammation of the myocardium. 

Myocardium - the actual heart muscle. 

Myoid cell- muscle-like cell located in the thymus. 

Myxovirus - the group ofviruses which include the influenza and parainfluenza viruses. 

Nasolabial Folds - the area between the nose and the lip. 

Nasopharyngeal- referring to the part of the throat above the soft palate. 

Nephritis - inflammation of the kidney. 

Nephrosis - any disease of the kidney. 

Nephrotoxicity - a poisonous effect on the kidney. 

NeuromuscularJunction - the junction between a nerve and the muscle which it controls. 

Neurotransmitter - a specific chemical which plays a role in the transmission ofan impulse from 

one nerve fiber to another. 

Nonsteroidal Anti-Inflammatory Drug - a type of drug which does as its name implies, it acts 

against inflammation and simple pains. 

Nuclear Matrix - a protein network found between the nucleolus and the nuclear membrane. 

Nuclear Ribonucleoprotein - a type of compound which is thought to be similar in nature to 

deoxyribonucleoproteins except that it is associated with RNA. 

Optic Disk - a white, round disk at the back of the eyeball where the optic nerve enters the eye. 

Orthopnea - inability to breathe except in an upright postion. 

Osteonecrosis - death of bone cells, often associated with bone disintegration. 

Osteoporosis - the readsorption of bone by the rest of the body. 

Pancreatitis - inflammation of the pancreas. 

Paramyxovirus - the group ofviruses which include the mumps, measles, and rubella viruses. 

Periarticular Soft Tissue - the tissue situated around ajoint. 

Pericarditis - inflammation of the pericardium. 

Pericardium - the membrane which surrounds the heart. 

Peripheral Nerves· the nerves which are not a part the central nervous system. 

Peripheral Neuritis - inflammation of the nerve endings. 

Phagocytosis - the active process of engulfing particulate matter within a cell. 

Phospholipid - a compound which contains a phosphorus and a fatty component. This com­

pound is found in tissues in much of the body. 

Plasma Cell- a sensitized B cell which secretes antibodies specific for a certain antigen. 

Platelet - a cytoplasmic fragment which takes an active part in the coagulation of blood and for­

mation of blood clots. 

Pleura - the membrane surrounding the lungs and lining the thoracic cavity. 

Pleurisy/Pleuritis - inflammation of the pleura. 

Pneumonitis - inflammation of the lung without gross toxicity 

Polyarteritis - inflammation of several arteries at the same time. 

Polymorphonuclear Leukocyte - a type of white blood cell that phagocytoses foreign material. 

Polymyositis - an inflammatory disorder of the skeletal muscle. 

Postsynaptic Terminal- the nerve ending found after the synapse. 
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Presynaptic Terminal- the nerve ending found before the synapse. 
Proliferating Cell Nuclear Antigen - a nuclear protein found most often in cells which are prolif­
erating. 
Proteinuria -large amounts of protein in the urine. 
Psychosis .. any major, severe form of prolonged mental disorder. 
Ptosis - drooping of the eyelids. 
Purpura - condition characterized by pinpoint, purplish red spots on the skin. 
Raynaud's Phenomenon .. attacks of paleness and blueness along with numbing of fingers and 
toes. 
Reovinu -a group ofviruses against which antibodies have been produced in patients with SLE. 
Retina .. the back part of the eye which is responsible for the ability to see. 
Rheumatoid Arthritis - an autoimmune disorder characterized by severe inflammation of the 
joints. 
Rheumatoid Arthritis Nuclear Antigen - one of the first nuclear an tigens which is was found to 
have antibodies produced against it in rheumatoid arthritis. 
Rheumatoid Factor - an antiimmunogloulin antibody directed aminly against IgG molecules. 
Ribosomes .. a particle which is found in the cytoplasm of a cell composed of protein and RNA. 
Roentgenograph - a photograph similar in nature to an X-ray only using roentgens. 
Rubella - a virus more commonly known as German measles. 
Sclerodactyly - localized scleroderma on the fingers and toes. 
Scleroderma - an autoimmune disorder characterized by a hardening and leather-like appear­
ance of the skin. 
Sendai Virus - a relative of the mumps virus. 
Septicemia .. the presence of bacterial toxins in the blood. 
Sjogren's Syndrome - an autoimmune disease which is often marked by a drying of the eyes and 
mouth. 
Smith (Sm) Antigen - a nuclear antigen against which antibodies are produced in SLE. 
Splenomegaly .. enlargement of the spleen. 
Subacute Bacterial Endocarditis .. inflammation of the lining of the heart caused by a bacterial 
infection. 
Subacute Sclerosing Panencephalitis - a fatal disease caused by a latent measles infection which 
reactivates to cause disintegration of the brain and the systems which the brain controls. 
Suppressor T Cell- a type ofT cell which turns ofT an immune response to a specific foreign 
antigen. 
Synapse - the region of contact between two nerves or one nerve and a muscle. 
Systemic Lupus Erythematosus - an autoimmune disease which affects all parts of the body char­
acterized by high levels of antinuclear antibodies. 
T Cell- a type oflymphocyte which originates in the bone marrow, but differentiates and 
matures in the thymus. 
Telangiectasia .. a disorder where the capillaries and small arteries become dilated. 
Tensilon - a short-acting anticholinesterase drug which is used to enhance the effects ofacetyl­
choline on a muscle. 
Thrombocytopenia - decrease in the number of blood platelets. 
Thymocyte - a lymphocyte in the thymus. 
Thymoma - tumor or cancer of the thymus. 
Thymus - a gland-like organ which regulates the differentiation and maturation of certain whit­
ed blood cells (T cells). 
Total Lymphoid Irradiation - a possible way to treat autoimmune disease by exposing lymphatic 
tissues to large doses of radiation. 
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Treponema pallidum - the organism which causes syphilis. 

Uremia - the presence of urinary constituents in the blood. 

Urinalysis - a test attempting to detect increased amounts of protein and cells in the urine, 

which is indicative of kidney problems. 

Vasculitic Lesions • lesions which are characterized by being slightly tender to the touch and 

somewhat hardened. 

DRUGS AND CHEMICALS 
OTCName Chemical Name Uses 
Tensilon edrophonium CI MG diagnosis 
Mestinon pyridostigmine Br MG treatment 
Prostigmin neostigmine Br MG treatment 
Mytelase ambenonium Cl MG treatment 
prednisone immunosuppressant 
azathioprine immunosuppressan t 
cyclophosphamide immunosuppressant 
Procan/ procainamide HCl for hypertension 
Pronestyl 
Apresoline hydralazine HCI for hypertension 
Dilantin diphenylhydan toin for convulsions 
Laniazid/ isoniazid for tuberculosis 
Nydrazid/ 
Teebaconin 
Cuprimine/ penicillamine RA treatment 
Depen Titratabs 
Tetracycline general antibiotic 
Atabrine quinacrine for skin lesions 
Plaquenil hydroxychloroquine for skin lesions 
Arahen chloroquine or skin lesions 
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